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ABSTRACT 
Cancer related mortality rate is exceptionally high in developing countries 
including Pakistan. Lack of awareness regarding early warning signs and potential 
risk factors often contributes to high mortality rate. Complex molecular 
mechanisms are involved in the pathogenesis of various malignancies. Nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) is one of the key 
pathways involved in cancer progression by cellular and immune regulation. This 
pathway is usually kept inactive in cytoplasm of normal cells by another group of 
proteins known as inhibitor of NF-κB (IκB). Degradation of IκB is regulated by a 
set of proteins called IκB kinases (IKKs) resulting in deregulated activation of 
NF-κB pathway in malignant cells. IKKs have been reported to interact with 
cellular Myelocytomatosis (c-Myc), thereby suggesting NF-κB-independent roles 
of IKKs in tumors. Fluorescence Resonance Energy Transfer (FRET) microscopy 
was employed to analyze the association of IKKs and c-Myc in human embryonic 
kidney (HEK 293) cell line. The current study revealed for the first time that the 
helix loop helix (HLH) and leucine zipper (LZ) domains of IKKα play an 
indispensable role in the interaction of IKKα with c-Myc. Further the effect of the 
IKKs and c-Myc interaction was tested at transcriptional and translational levels. 
IKKs were not found to affect the c-Myc expression at transcriptional and 
translational level, but IKKs were found to reduce transcriptional activity of c-
Myc, thereby suggesting a possible regulatory role of IKKs on c-Myc and cancer. 
The interaction of IKKα with c-Myc was found to be comparatively stronger as 
compared to IKKβ. Therefore, in order to explore the independent role of IKKα in 
Breast cancer, the paraffin embedded tissue sections were immunohistochemically 
stained with IKKα. The immunohistochemical analysis of IKKα protein showed 
its decreased expression in Progesterone receptor (PR) positive BC biopsies 
suggesting an inverse correlation between the two proteins. An association 
between IKKα expression with tumor grade was observed but was found to be 
statistically insignificant. 
                                                                                                                      Abstract 
 xxii
Proto-oncogenes such as c-Myc are often found to be up-regulated in most 
of the human neoplasmas often in association with genetic changes including 
single nucleotide polymorphism (SNPs). Therefore, the effect of 27 non 
synonymous SNPs (nsSNPs) on the structure and function of c-Myc protein was 
found through an in silico analysis. Among the various nsSNPs studied; 
rs114570780 (Tyr47His), rs150308400 (Cys148Tyr), rs137906262 (Leu159Ile) 
and rs200431478 (Ser362Phe) were found to have noteworthy biological worth 
and may be considered while developing personalized therapeutic approaches. 
Taken together, these findings have potential implications in the development of 
diagnostics and therapeutic approaches against malignancies. 
 
Chapter 1                                                                                                Introduction 
1 
 
Chapter 1 
INTRODUCTION 
Cancer is a group of diseases resulting from an uncontrolled division of 
abnormal cells with the propensity to invade or spread to other parts of the body. 
Presently, there are more than 100 types of cancers that can affect humans (Smyth 
et al., 2006). Cancer is found to be the most frequent cause of death (accounting 
for 13 % of total deaths) across the globe. In last few decades tremendous work has 
been done to investigate the pathogenic mechanisms involved in cancer 
progression but still a lot is to be done (Hoesel and Schmid, 2013).   
Cancer progression and sustenance is directly controlled by proper 
regulation of molecular activities as a signaling cascade. Abnormal activation of 
these pathways leads to excessive inflammation, escape from immune system and 
ultimate development of cancer (Hayden and Ghosh, 2012). A significant hallmark 
of cancer pathogenesis involves regulation of well known nuclear factor kappa 
light chain enhancer of activated B cells (NF-κB) signaling pathway. Aberrant 
activation of NF-κB in tumor microenvironment leads to excessive inflammation 
and cancer progression. (Hanahan and Weinberg, 2011).  
Activity of NF-κB transcription factors is controlled by a group of 
inhibitory molecules called inhibitor of NF-κB (IκB). These inhibitors make 
complexes with NF-κB through non-covalent association thus inhibiting its 
translocation to the nucleus (Whiteside and Israel, 1997). IκB is phosphorylated by 
the catalytic subunits of IKK complex, called IκB kinase alpha (IKKα) and IκB 
kinase beta (IKKβ), allowing the ubiquitinylation of IκB and its degradation by the 
proteasome. Degradation of IκB leads to the liberation of NF-κB subunits to 
translocate to the nucleus where they bind to specific DNA targets as transcription 
factors to promote their activation (Bonizzi and Karin, 2004; Hayden and Ghosh, 
2012).  
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Accumulating evidence has indicated involvement of IKKα in endurance 
and development of cancers independent of NF-κB (Israel, 2010; Jiang et al., 
2010). IKKα potentially regulates cyclin D1 expression which is a well known 
oncogene involved in the pathogenesis of the breast cancer (BC) (Arnold and 
Papanikolaou, 2005). Moreover, the modulation of E2F1 transcription factor and 
consequent regulation of oestrogen induced cell-cycle progression reveal a 
considerable role of IKKα in BC (Tu et al., 2006). In an in vitro study the invasion 
and propagation of BC cells is reported to be mediated by IKKα downstream of the 
membrane bound epidermal growth factor receptor Her2 (Merkhofer et al., 2010). 
More detailed molecular characterization and exploration of new targets of IKKs 
can help to clarify their potential role in cancer biology. 
IKKα regulated transcription factors such as NF-kB and E2F are directly 
involved in expressional regulation of a pleiotropic oncogenic Myc family of 
proteins.  (Wierstra and Alves, 2008; Levens, 2010). c-Myc belongs to the basic 
helix-loop-helix leucine zipper (bHLHLZ) containing family of transcription 
factors (TFs) and is among the most well characterized and influential transcription 
factors as it is evidently involved in the regulation of almost 15% of human genes 
(Xu et al., 2010). Extensive research during last three decades manifested the 
crucial role of Myc protein in cell growth, proliferation, apoptosis, gene expression 
and cancer metabolism (Henriksson and Luscher, 1996; Thompson, 1998; Lee and 
Dang, 2006; Miller et al., 2012).  
c-Myc is actively involved in the regulation of a variety of genes related to 
the cancer development and persistence (Gustafson and Weiss, 2010). The c-Myc 
plays a role in the cancer development either by translocation or extrinsically 
deactivating the critical regulatory mechanisms (Dave et al., 2006). c-Myc plays a 
crucial role in angiogenesis (Baudino et al., 2002) along with the regulation of 
metabolism, cell growth and metastasis to promote oncogenesis (Adhikary and 
Eilers, 2005; Dang et al., 2006). Moreover, c-Myc activates cyclin D1, CDC25A, 
CDK4, E2F1 and E2F2 genes to endorse cell cycle progression (Meyer and Penn, 
2008) and transcriptional repression of the p27 CDK inhibitor gene by c-Myc 
assists in cell proliferation (Yang et al., 2001).  
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BC is one of the most commonly diagnosed malignancies and the second 
leading cause of cancer-related deaths among women worldwide (Jemal et al., 
2011). According to the World Health Organization (WHO) more than 1.4 million 
people are victimized globally by BC and 458,000 die of this disease every year 
(Asif et al., 2014). BC associated mortality rate is on rise in developing countries 
(Forouzanfar et al., 2011). Developing countries are predicted to face rapid death 
rate due to BC as compared to the developed countries (Donnelly et al., 2013). 
Pakistan has highest incidence and mortality rate of BC among Asian countries 
(Bhurgri et al., 2000; Asif et al., 2014).  
One of the leading causes of BC related mortality is the late diagnosis in 
Pakistan. Late stage diagnosis usually involves metastasis and is hard to treat thus, 
reduces the survival rate. Likelihood of up to 5 years survival is about 85% among 
the cases diagnosed at an early stage while it reduces to just 10 % among cases 
diagnosed at BC stage IV (Gilani et al., 2003). Lack of public awareness about 
preventable risk factors and early warning signs is main cause of late diagnosis. 
Increase in survival rate of patients can be achieved by a significant approach of 
persuading awareness in population, better screening and in time detection of 
breast cancer at an initial stage.   
Going through all reported data this study was aimed to explore:  
 In vitro study of molecular role and cross talk between IKKs and c-
Myc onco-protein.  
 In silico analysis of genetic variations in c-Myc onco-protein and 
their structural and functional role.  
 In vivo expression of IKKα in breast cancer patients and its 
correlation with clinicopathological features of Pakistani 
population. 
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Chapter 2 
REVIEW OF LITERATURE 
Cancer is a group of diseases involving abnormal cell growth with the 
propensity to invade or spread to other parts of the body. There are more than 100 
different types of known cancers that can affect humans (Smyth et al., 2006). In 
last few decades tremendous steps have been taken to explore the mechanisms 
involved in cancer progression. So far, numerous discoveries are made in this 
concern, but slew of still unanswered questions cued that cancer is actually an 
infinitely complex disease (Hayden and Ghosh, 2012). Knowledge to date 
indicates that fortunately, one third of all cancers can be prevented and further one 
third can also be cured if diagnosed at an early stage (Parkin, 1994).  
2.1 CANCER AND SIGNALING PATHWAYS  
Cell functions are carried out by controlled activities of molecules working 
together in form of a signaling cascade. Abnormal activation of these pathways 
leads to development of cancer. Considerable role of several signaling pathways in 
development of cancers has recently been made evident. Identification of 
extracellular environment and consequential cellular response involves cross talk 
of various signaling pathways (Eroles et al., 2012). Any disruption in these 
integrated pathways can lead to initiation and progression of cancer. The epidermal 
growth factor receptor (EGFR) of ErbB family is abnormally activated in several 
cancers including BC (Carpenter, 1987). Four structurally related receptors of 
ErbB family include HER1/ErbB-1/ EGFR, HER2/ ErbB-2, HER3/ErbB-3 and 
HER4/ErbB-4 (Martin, 2006). The ligand binding to cysteine-rich extracellular 
domain activates EGFR which undergoes autophosphorylation at the tyrosine 
kinase domain consequently activating EGFR regulated downstream signaling 
pathways including signal transducer and activator of transcription (STAT), 
mitogen-activated protein kinases/extracellular signal-regulated kinases 
(MAPK/ERK), phosphatidylinositol 3' -kinase (PI3K/AKT), and protein kinase C 
pathways (Atalay et al., 2003).  
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The STATs family of transcription factors mediates changes in gene 
expression after interaction of cytokines and growth factors with their receptors on 
the cell surface. In general the STATs remain transiently activated but tyrosine-
phosphorylated STATs especially STAT3 and STAT5 are reported to be 
constitutively active in a wide range of human cancers (Hynes and Gullick, 2006). 
STAT3 is implicated to promote BC development. Elevated levels of activated 
STAT3 is reported to be associated with increased breast cancer cell proliferation, 
endurance and metastasis while suppression of STAT3 expression in breast cancer 
leads to apoptosis, inhibition of cell growth and reduction of invasive potential. 
(Sato et al., 2011).  
Highly conserved Notch signaling pathway involves four Notch receptors 
and five ligands in mammals. It plays crucial role in cell growth, apoptosis, 
differentiation and angiogenesis through transcriptional regulation of cyclin D1, 
p21, c-Myc, Nuclear factor kappa light chain enhancer of activated B cells (NF-
κB), vascular endothelial growth factor receptors (VEGFR) and HER2 (Al-
Hussaini et al., 2011). Disruption of the Notch pathway has been implicated in 
development of BC. It interacts with HER2 signaling pathway, which is active in 
approximately 20% BC cases and results in more aggressive outcome of the 
disease. Expression of HER2 is down regulated by inhibition of Notch signaling 
pathway (Osipo et al., 2008). This pathway significantly promotes tumor growth 
and proliferation by renewal of treatment resistant tumor-initiating cells (TIC) and 
endorsement of tumor angiogenesis through MAPK activation (Zeng et al., 2005). 
Aberrant activation of the Hedgehog (HH) signaling pathway has also been 
implicated in development of skin, digestive tract, breast, prostrate, brain and lung 
cancer (Ali, 2012). HH signaling is reported to be involved in invasiveness and 
metastasis of cancer (Feldmann et al., 2007). 
2.2 CANCER AND NF-κB SIGNALING PATHWAY 
A significant hallmark of cancer pathogenesis involves regulation of well 
known NF-κB signaling pathway which is conserved in multi-cellular animals 
(Hanahan and Weinberg, 2011). The tumor microenvironment deregulates the 
pathway, leading to inflammation and cancer development. Aberrant activation of 
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NF-κB provides mechanistic basis for a number of cancers. Physiological, 
physical, or/and oxidative stress results in inflammation that can activate NF-κB 
signaling pathway (Ben-Neriah and Karin, 2011). Inflammation generally and NF-
κB pathway particularly exhibit a double-edged role in cancer development. 
Constitutive activation of NF-κB leads to pro-tumorigenic role in a number of 
cancers. While on the other hand, activation of the NF-κB signaling pathway by 
activity of cytotoxic immune cells results in elimination of transformed cancer 
cells (Disis, 2010). This anti-tumorigenic role of the immune system involving NF-
κB pathway has been designated as cancer immune surveillance (Smyth et al., 
2006). As this immune defense system of the body against cancer, is not strong 
enough to eliminate all the cancer cells thus a successive shift to an equilibrium 
phase and then an escape phase makes the cancer cells able to surpass the immune 
system (Dunn et al., 2004).  
NF-κB fuels inflammation through production of Cyclooxygenase 2 (COX-
2) enzymes and inflammatory cytokines such as tumor necrosis factor α (TNFα), 
interleukin-1 (IL-1), IL-6 and IL-8. Moreover, it causes stimulation of cell 
proliferation, promotion of inflammation and evasion of apoptosis by activation of 
cancer stem cells (CSCs) (Chefetz et al., 2011) and up-regulation of several anti-
apoptotic genes such as B-cell lymphoma 2 (BCL-2), BCL-XL, caspase8 and  Fas-
Associated protein with Death Domain (FADD) like apoptosis regulator (CFLAR) 
and cellular inhibitor of apoptosis proteins (cIAPs) (Basseres and Baldwin, 2006) 
(Figure 2.1).  
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Figure 2.1:  Role of NF-κB signaling pathway in cancer cell progression.    
NF-κB signaling is reported to play a vital role in cancer progression by 
controlling up-regulation of VEGF and VEGFR responsible for enhanced blood 
supply to tumors through vascularization and angiogenesis. NF-κB is also involved 
in epithelial to mesenchymal transition and metastasis by targeting the adhesion 
factors including the vascular cell adhesion molecule 1 (VCAM-1), intercellular 
cell adhesion molecule 1 (ICAM-1) and matrix metalloproteinases (MMPs) which 
help in loosening the extracellular matrix for evasion of the cancer cells (Huber et 
al., 2004; Hoesel and Schmid, 2013) (Figure 2.1). Enhanced release of cytokine, 
presence of genetic variations in NF-κB genes and/or oncogenes involved in 
activation of NF-κB signaling pathway can directly elevate NF-κB activity in 
tumor microenvironment (Ben-Neriah and Karin, 2011). The steroid hormone 
receptors PR and ER also play significant roles in inflammation and cancer 
development. PR and NF- B are reported to suppress each other’s activity (Van 
Der Burg and Van Der Saag, 1996). 
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2.2.1 Members of NF-κB Signaling Pathway  
Initially the proteins of NF-κB family were characterized due to their 
interaction with the immunoglobulin light chain enhancer of the B cells (Sen and 
Baltimore, 1986). The family of NF-κB transcription factors comprises mainly five 
proteins i.e. RelA (p65), RelB, c-Rel, NF-κB1 (p105/p50) and NF-κB2 (p100/p52) 
(Nabel and Verma, 1993) (Figure 2.2). A conserved Rel homology domain (RHD) 
of approximately 300 amino acids is common among these proteins. RHD is 
responsible for homo and heterodimerization along mediation of DNA contact. C-
terminal trans-activation domains (TAs) are found among subset of RelA, RelB 
and c-Rel proteins which are needed for transcriptional activity (Shih et al., 2011). 
Initially the NF-κB1 (p105) and NF-κB2 (p100) are produced as large inactive 
precursors that are ultimately degraded through ubiquitin proteasomal pathway to 
yield smaller active proteins; p50 and p52 respectively (Ghosh et al., 1998). These 
active smaller proteins then form homo and heterodimers and are translocated to 
the nucleus where they bind to specific DNA targets as transcription factors to 
promote their activation (Bonizzi and Karin, 2004; Hayden and Ghosh, 2012).  
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Figure 2.2: Members of the NF-κB family of proteins.  NF-κB family of proteins 
contains five members; RelA (p65), RelB, c-Rel, p105 and p100. p105 and p100 
yield their shorter forms p50 and p52, respectively. All members contain a N-
terminal Rel homology domain (RHD) while three members (RelA, RelB and c-
Rel) harbor C-terminal transactivation domain (TA). Leucine zipper (LZ) is 
present in RelB while Ankyrin (ANK) repeats and death domain (DD) are found in 
p105 and p100 (Hoesel and Schmid, 2013). 
2.2.2 Inhibitor of NF-κB (IκB)  
Activity of NF-κB transcription factors is controlled by a group of 
inhibitory molecules called inhibitor of NF-κB (IκB). The IκB family of proteins 
includes three members; IκBα, IκBβ and IκBε (Figure 2.3). Ankyrin (ANK) 
repeats are present among these proteins which are responsible for making 
complexes with NF-κB through non covalent association thus inhibiting its 
translocation to the nucleus (Hoesel and Schmid, 2013). In addition to the ANK 
repeats IκBα and IκBβ are characterized by the presence of PEST domains that are 
rich in proline (P), glutamate (E), serine (S) and threonine (T) and are necessary 
for constitutive turnover (Figure 2.5). Phosphorylation of IκB on two nearby serine 
residues (Ser32/Ser36; found in the N-terminal signal-response domain) is 
followed by polyubiquitination by specific Skp1-Cul1-F-box (SCF) type E3 
ubiquitin-protein ligase and ultimate degradation by 26S proteasome (Karin and 
Ben-Neriah, 2000; Chen, 2005; Schmid and Birbach, 2008).  
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Figure 2.3: Members of the IκB family of proteins. Inhibitor of NF-κB (IκB) 
family of proteins includes three members; IκBα, IκBβ, IκBε. In addition to the 
ANK repeats IκBα and IκBβ have PEST domains (Hoesel and Schmid, 2013). 
2.2.3 IKK Complex  
Cytoplasmic IκB kinase (IKK) complex of about 700–900 kD was 
discovered to be responsible for phosphorylation of IκB. The IKK complex/IKK 
signalosome consists of two catalytic subunits: IκB kinase alpha 
(IKKα/IKBKA/IKK1), IκB kinase beta (IKKβ/IKBKB/IKK2) (Zandi et al., 1997) 
and a non-enzymatic accessory NF-κB essential modulator (NEMO) (Yamaoka et 
al., 1998) named IKK gamma (IKKγ) (Rothwarf et al., 1998) (Figure 2.4). IKKα 
and IKKβ exhibit 50% similarity in sequence. IKKs contain an amino terminal 
kinase domain, helix-loop-helix (HLH) domain and a leucine zipper (LZ). IKKα 
contains a nuclear localization signal (Sil et al., 2004) and is reported to shuttle 
between nucleus and cytosol. Despite the structural similarity of two kinase 
subunits and their presence in the same complex, they involve distinct proteins to 
perform different functions in the cell. It leads to two signaling pathways; 
canonical and non-canonical pathways (Hoesel and Schmid, 2013).  
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Figure 2.4: Members of IκB kinase (IKK) complex. IKK complex includes 
essential modulator (NEMO or IKKγ), IκB kinase α, (IKKα) and IκB kinase β 
(IKKβ). Essential domains of IKKs are Coiled-coil domain (CC), Leucin-zipper 
(LZ), death domain (DD), zinc-finger domain (ZF), helix-loop-helix domain 
(HLH), NEMO-binding domain (NBD) (Hoesel and Schmid, 2013). 
2.2.4 Canonical and Non-canonical NF-κB Signaling Pathway 
Canonical pathway is initiated by proinflammatory stimuli, such as 
lipopolysaccharides (LPS), TNFα and IL-1β and involves phosphorylation of IκBα 
principally by IKKβ (Perkins and Gilmore, 2006; Schmid and Birbach, 2008). 
Non-canonical pathway is initiated by different stimuli such as B-cell activation 
factor (BAFF), CD40 ligand, and lymphotoxin β (LTβ) and predominantly 
involves NF-κB inducing kinase (NIK) which phosphorylates IKKα (Park et al., 
2005) (Figure 2.5).  
In the canonical NF-κB signaling pathway the tumor necrosis factor α 
(TNFα), lipopolysaccharides (LPS) or interleukin-1 (IL-1) activate their respective 
receptors. Involvement of a number of proteins results in activation of IKKβ, 
which phosphorylates IκBα. This phosphorylation is followed by 
polyubiquitination and proteasomal degradation of IκBα liberating NF-κB to 
translocate into the nucleus to start transcription activation of target genes. The 
canonical NF-κB signaling pathway results in transcriptional activation of different 
cytokines like TNF-α, IL-1β, IL-6 and Granulocyte-macrophage colony-
stimulating factor (GMCSF), chemokines e.g. IL-8, monocyte chemoattractant 
protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), adhesion 
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molecules (VCAM-1, ICAM-1, E-selectin) and enzymes like COX-2 and 
phospholipase A2 (PLA2) (Luo et al., 2005).   
In the non-canonical NF-κB signaling pathway, attachment of CD40 ligand, 
B-cell activation factor (BAFF) or lymphtoxin β (LTβ) to their respective receptors 
induces NF-κB-inducing kinase (NIK) which activates IKKα. The p100 after being 
phosphorylated by IKKα undergoes polyubiquitination and subsequent 
proteasomal processing to p52. Heterodimers of p52 and RelB are then 
translocated into the nucleus to initiate transcriptional activation of target genes 
(Figure 2.5). The non-canonical NF-κB signaling pathway results in transcriptional 
activation of different cytokines (BAFF), chemokines like B lymphocyte 
chemoattractant (BLC), secondary lymphoid tissue chemokine (SLC), stromal 
cell–derived factor-1α (SDF-1), Epstein-Barr virus–induced molecule 1 ligand 
chemokine (ELC) and lymphoid organogenesis genes like GlyCAM-1 (Luo et al., 
2005).  
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Figure 2.5:  The canonical and non-canonical NF-κB signaling pathway. Canonical 
NF-κB signaling pathway is triggered by attachment of tumor necrosis factor α 
(TNFα), lipopolysaccharides (LPS), or interleukin-1 (IL-1) to their respective 
receptors.  IKKβ is activated through involvement of a variety of adapter proteins 
and signaling kinases and phosphorylates IκB. Phosphorylated IκB is subjected to 
polyubiquitination and subsequent degradation allowing NF-κB homo or 
heterodimers to translocate to the nucleus and activate transcription of target genes 
(TNF, IL-1, IL-6 etc.). Non-canonical NF-κB signaling pathway is activated by 
attachment of CD40, B-cell activation factor (BAFF) or lymphtoxin β (LTβ) to 
their respective receptors. This activation leads to activation of IKKα through NF-
κB-inducing kinase (NIK). Activated IKKα then phosphorylates p100 which is 
further subjected to polyubiquitination and proteasomal processing to p52. 
Heterodimers of p52-RelB is then translocated to the nucleus for transcriptional 
activation of target genes (BCL, BAFF etc.). 
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2.2.5 Role of IKKs in Cancer  
Accumulating evidences have indicated that IKK family of proteins 
regulates many physiological and pathological processes by targeting a variety of 
substrates, which significantly widens their crucial role in development of cancers 
where their activity is enhanced and constitutive (Israel, 2010; Jiang et al., 2010). 
IKKs can also affect a number of proteins independent of NF-κB involvement (Lee 
and Hung, 2008; Chariot, 2009). IKKα affects gene expression and function of 
cyclin D1 which is a major driver in the pathogenesis of multiple types of human 
cancers (Albanese et al., 2003). Involvement of cyclin D1 in growth factor 
signaling pathway and cell cycle regulation designate it to be a potent oncogene. 
Activation and dysregulation of the cyclin D1, often by amplification or 
rearrangement result in loss of normal cell cycle control during tumorigenesis. 
More than 50% of human breast cancers are characterized by Cyclin D1 
overexpression. (Arnold and Papanikolaou, 2005; Velasco-Velazquez et al., 2011). 
IKKα regulates cyclin D1 through transcriptional activation, phosphorylation of 
cyclin D1 (Kwak et al., 2005), estrogen receptor-α (ERα) (Park et al., 2005) and 
steroid receptor coactivator (SRC3) (Wu et al., 2002). IKKα is also reported to 
induce the promoter of cyclin D1 through activation of p52 (Rocha et al., 2003) 
and stabilization as well as phosphorylation of β-catenin oncoprotein. IKKα 
inhibits polyubiquitylation of β-catenin thus increases its protein level and 
transcriptional activation (Carayol and Wang, 2006).  
 Activation of IKKβ is reported to stimulate pro-inflammatory, proliferative 
and anti-apoptotic pathways (Luo et al., 2005) (Kucharczak et al., 2003) however, 
its pro-apoptotic role can also not be ignored (Herrmann et al., 2005; Baxter et al., 
2006). IKKβ can promote tumor endurance by phosphorylating FOXO3a which is 
a well known tumor suppressor that can induce apoptosis and cell-cycle arrest. 
This phosphorylation leads FOXO3a to nuclear exclusion and ultimate degradation 
(Hu et al., 2004). Conversely, IKKβ is also found to induce apoptosis by activating 
FOXO3a in regressing mammary glands (Baxter et al., 2006). IKKβ helps in cell 
proliferation by phosphorylating 14-3-3β protein (Gringhuis et al., 2005). IKKβ 
regulates pro-proliferative MAPK signaling pathway by inducing proteolysis of 
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p105 subunit of NF-κB (Beinke et al., 2004; Waterfield et al., 2004) and 
phosphoralyting an adaptor docking protein 1 (DOK1) which down regulates 
MAPK and promotes cell motility (Lee et al., 2004).  
Some transcriptions factors are also among potential substrates of IKKs.  
IKKα directly phosphorylates protein inhibitor of activated STAT1 (PIAS1) upon 
TNFα stimulation. Phosphorylated PIAS1 is then recruited to the promoter of NF-
κB target genes and inhibits the DNA-binding of p65 consequently repressing the 
transcription of genes responsible for production of pro-inflammatory cytokines 
and chemokines (Liu et al., 2007). Moreover, modulation of E2F1 transcription 
factor and consequent regulation of estrogen induced cell-cycle progression reveal 
a considerable role of IKKα in breast cancer (Tu et al., 2006). IKKs are also 
reported to prolong the stability of Myc oncoprotein (Yeh et al., 2011). More 
detailed molecular characterization and exploration of new targets of IKKs can 
help to clarify their potential role in cancer biology. 
2.3 MYC PROTEIN 
The pleiotropic oncogenic c-Myc protein was first identified as a homolog 
of v-Myc avian myelocytomatosis viral oncogene about 3 decades back 
(Vennstrom et al., 1982). Myc family of oncoproteins arises from three distinct 
gene family members; c-Myc, N-Myc, and L-Myc. Although these proteins differ 
in potency (Nesbit et al., 1998) and patterns of expression (Zimmerman et al., 
1990), they are functionally related. Myc belongs to the basic helix-loop-helix 
leucine zipper (bHLHLZ) containing family of transcription factors and is among 
the most well characterized and influential transcription factors as it is evident by 
its involvement in the regulation of almost 15% of human genes (Xu et al., 2010). 
N-terminal region contains four virtually identical and highly conserved domains, 
identified as Myc Box I (MBI), MBII, MBIII and MBIV (Cowling et al., 2006). N-
terminal region contains several well characterized phosphorylation and 
ubiquitination sites (Figure 2.6). The basic region (BR) of c-Myc mediates the 
DNA while the helix-loop-helix (HLH) and leucine zipper (LZ) domains mediate 
heterodimerization with other proteins (Hann, 2006). Extensive research during 
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last three decades manifested the crucial role of Myc protein in cell growth 
(Henriksson and Luscher, 1996), proliferation (Lemaitre et al., 1996), apoptosis 
(Thompson, 1998), gene expression (Lee and Dang, 2006) and cancer metabolism 
(Miller et al., 2012). 
 
 
Figure 2.6: Schematic diagram of the significant domains and position of 
phosphorylation and ubiquitination in c-Myc protein. It details the location of 
highly conserved Myc homology boxes (MBI, MBII, MBIII and MBIV), basic 
region (BR), helix-loop-helix (HLH) and leucine zipper (LZ) domains. The 
numbers below represent the amino acid that borders each significant domain of 
protein. Specific N-terminal features, including the location of phosphorylation and 
ubiquitination (lysine residues) are indicated on upper side. 
2.3.1 c-Myc Isoforms 
Translational initiation of c-Myc gene at different start sites results in the 
production of three isoformes i.e. c-Myc1, c-Myc2/c-Myc (Hann et al., 1988) and 
c-MycS (Hann, 1995) which have similar carboxy terminus while different N-
terminal region. Translational start at AUG start site in second exon encodes a 64 
kDa isoform i.e. c-Myc2 comprising 439 amino acids. Another translational start at 
a non canonical CUG located 15 codons upstream of the c-Myc2 initiation start 
results in addition of 15 amino acids at the N-terminal region and production of c-
Myc1 (p67) , a 67 kDa longer isoform of 454 amino acids (Hann et al., 1988). 
Translational start at AUG site positioned 100 codons downstream of c-Myc2 start 
site yields N-terminally-truncated 339 amino acid protein called c-MycS. This 
isoform lacks well conserved MBI motif found in 100 amino acids region of the 
trans-activation domain at N-terminus in major isoform (Spotts et al., 1997).  
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2.3.2 c-Myc Regulation  
The Myc protein makes a heteromeric complex with Myc associated factor 
X (MAX), which binds to E-boxes to activate transcription (Blackwood and 
Eisenman, 1991). Many coactivators and protein complexes also recruit to the E-
box elements for this transcriptional initiation (Adhikary and Eilers, 2005). Myc 
expression in turn is regulated by other transcription factors such as NF-κB, E2F, 
STAT, and β-catenin (Wierstra and Alves, 2008; Levens, 2010). Myc mediated 
biological activities are mainly regulated by an intricate series of phosphorylations 
and dephosphorylations. In asynchronously growing cells , Thr58 (73 in c-Myc2) , 
Ser62 (77 in c-Myc2), Ser71(86 in c-Myc2) (Gupta et al., 1993; Henriksson et al., 
1993; Pulverer et al., 1994), Ser82 (97 in c-Myc2) and Ser164 (179 in c-Myc2) 
(Lutterbach and Hann, 1997) are identified to be the potential phosphorylation sites 
so far (Figure 2.6).  
The conserved region MBI of c-Myc1 harbors crucial Thr58 and Ser62 at 
N-terminus. Selection of proline-directed kinase (s) to phosphorylate c-Myc is 
dependent on stimuli and cellular conditions. Phosphorylation of Myc at Ser62 by 
the c-Jun N-terminal kinase (JNK), extracellular signal regulated kinase (ERK) or 
cyclin-dependent kinase 1 (CDK1) results in stability of protein (Hann, 2006). 
Then Thr58 is phosphorylated by glycogen synthase kinase 3 (GSK3) (Gregory et 
al., 2003)  followed by dephosphorylation at Ser62 by protein phosphatase 2A 
(PP2A). At this stage monophosphorylated protein is subjected to 
ubiquitin/proteasome system for degradation. Although the advancement in 
research has revealed noteworthy effects of this kinase/phosphatase system on 
biological and molecular activities of c-Myc, however, the knowledge about exact 
mechanism and involved cofactors is still deficient (Hann, 2006; Wierstra and 
Alves, 2008). Some unidentified kinases can be involved in this outcome. 
2.3.3 c-Myc and Cancer  
c-Myc is actively involved in regulation of a variety of genes related to 
cancer development and persistence (Gustafson and Weiss, 2010). Lower 
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expression of c-Myc in normal resting cell becomes enormously high in the 
transformed cell stimulated via a broad range of signaling pathways, designating it 
to be an early response gene. It is not clear whether c-Myc over expression is the 
cause or the consequence of cell transformation (Miller et al., 2012). The c-Myc 
plays a role in cancer development either by translocation or extrinsically 
deactivating the critical regulatory mechanisms (Dave et al., 2006). Induction of c-
Myc in most of the common cancers is typically brought about by gene 
amplification (Vita and Henriksson, 2006). Not only the number of copies of c-
Myc (Escot et al., 1986; Mariani-Costantini et al., 1988) but the frequency of gene 
amplification is noteworthy in various human malignancies (Singhi et al., 2012).  
c-Myc plays a crucial role in angiogenesis (Baudino et al., 2002) along 
with regulation of metabolism, cell growth and metastasis to promote oncogenesis 
(Adhikary and Eilers, 2005; Dang et al., 2006). c-Myc brings about remarkable 
changes in cell morphology and promotes human mammary epithelial to 
mesenchymal transition (EMT) (Cowling and Cole, 2007). In breast cancer cells c-
Myc regulates G1-S transition of cell cycle by activation of cyclin E/CDK2 and 
repression of CDK inhibitor p21 (Prall et al., 1998; Mukherjee and Conrad, 2005). 
Moreover, c-Myc activates cyclin D1, CDC25A, CDK4, E2F1 and E2F2 genes to 
endorse cell cycle progression (Meyer and Penn, 2008). Transcriptional repression 
of the p27 CDK inhibitor gene by c-Myc assists in cell proliferation (Yang et al., 
2001).  
2.3.4 c-Myc Polymorphisms and Cancer  
Cancer risk is also influenced by the existing polymorphisms in the 
genome. One of the most frequent types of polymorphisms found in human 
genome is single nucleotide polymorphisms (SNP) (Noreen et al., 2012). Generally 
the SNPs associated with disease risk are missense or nonsynonymous SNPs 
(nsSNPs) involving substitution of amino acids. These SNPs are likely to bring 
structural and functional changes in the protein. Genetic variations in cis-regulators 
of transcription at 8q24 can significantly change the germline expression levels of 
c-Myc thus contribute to cancer susceptibility (Sole et al., 2008). Many studies are 
conducted to find association of a well documented SNP; rs13281615 harboring 
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the non-coding chromosomal region 8q24 near c-Myc and susceptibility of breast 
cancer, prostate cancer and colorectal cancer (Tomlinson et al., 2007; Meyer et al., 
2009; Pei et al., 2013). However, the results were inconsistent.  
A meta-analysis including more than 100,000 subjects was performed to 
evaluate the role of this SNP in risk of breast cancer development. Increased risk of 
breast cancer development was found to be significantly associated with presence 
genotype “GG” (OR: 1.20, 95% CI: 1.12–1.29, p value: 0.001), and allele “G” 
(Odds Ratio (OR): 1.10, 95% Confidence interval (CI): 1.06–1.14, p value: 0.001) 
while the genotype “AA” was found to be a protective factor against risk of breast 
cancer development (OR: 0.89, 95% CI: 0.84–0.93, p value: 0.001) (Gong et al., 
2013). 
Chromosomal region 8q24.21 harbors another discussable cancer risk SNP; 
rs6983267. Presence of allele “G” is variably frequent among all the populations 
ranging from 31% in native Hawaiians to 85% in African American population. In 
Europeans the allele frequency is around 50% (Wang et al., 2014). The rs6983267 
is reported to up regulate the c-Myc transcription (Takatsuno et al., 2013) and alter 
the physical interactions of c-Myc by affecting binding of transcription factor 7-
like 2 (TCF7L2) and TCF4 (Pomerantz et al., 2009). Presence of rs6983267 is 
associated with susceptibility to gastric cancer, inflammatory breast cancer, 
prostate cancer, colorectal cancer and colorectal adenoma (Guo et al., 2011; 
Bertucci et al., 2012; Os'kina et al., 2012; Wang et al., 2014).  
A cluster of four pathogenetically valuable nsSNPs; VAR_063384 
(Glu39Asp), VAR_063385 (Pro57Ser), VAR_063386 (Pro59Ala) and 
VAR_063387 (Asn86Thr) was reported to harbor 2nd and 3rd exon of c-Myc2 
trans-activation domain in Burkitt lymphoma samples (Bhatia et al., 1993). A rare 
nsSNP (rs4645959) lying in N-terminal trans-activation domain of c-Myc2 was 
reported to be putatively functional. Heterozygous carriers of this variant among 
Polish and German subjects were observed to have an increased risk of familial 
breast cancer (Wirtenberger et al., 2005). Later on a large population based 
centralized pathology review was conducted revealing no biological relevance of 
rs4645959 with risk, tumor characteristics or endurance of breast cancer 
(Figueiredo et al., 2007). Molecular epidemiological association studies mainly 
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focused on the nsSNPs lying in coding region of the gene (Ramensky et al., 2002; 
Savas et al., 2004; Zhu et al., 2004). Studying the structural and the functional 
impact of the nsSNPs on the protein can assist in the selection of functionally 
important nsSNPs.  
2.4 BREAST CANCER 
A group of uncontrollably proliferating cancer cells which originates from 
cells of the breast is known as BC. This malignancy can spread to surrounding and 
distant parts of the body. Breast cancer is the most commonly diagnosed 
malignancy and the second leading cause of cancer-related deaths among women 
across the globe (Jemal et al., 2011). According to World Health Organization 
(WHO) more than 1.4 million people are victimized globally by breast cancer 
458,000 die of this disease every year (Asif et al., 2014). Male breast cancer is rare 
and is not thoroughly investigated (Johansson et al., 2014).   
BC diagnosis has been regularized in developed countries in 1980, however 
the BC incidences and the associated mortality rate is on rise in developing 
countries (Forouzanfar et al., 2011). Developing countries are predicted to face 
rapid death rate due to BC from 2002 to 2020 as compared to the developed 
countries (Donnelly et al., 2013). Information regarding morbidity and mortality of 
BC in Pakistan has been inadequate due to lack of cancer registration system at 
national level. One in every nine Pakistani women is diagnosed to be a breast 
cancer patient thus making the Pakistan a country with highest incidence rate of 
BC among Asian countries (Bhurgri et al., 2000; Asif et al., 2014). Despite of 
same socio-cultural environment in Pakistan and India the occurrence rate of breast 
cancer among Pakistani women is significantly higher (50/100,000) than that of 
Indian women (19/100,000) (Rasheed, 2013).   
The female breast tissue is complex overlying the chest (pectoral) muscles. 
Breast has a number of lobules (milk producing glands) which have small sacs 
called alveoli. The lobules are linked together by a number of small ducts which 
ultimately open into larger ducts at areola. This network of ducts is responsible for 
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supply of milk to the nipple during breast feeding. Spaces around the lobules, 
ducts, blood and lymphatic vessel are filled with ligament, fat and connective 
tissue (cancer.org, 2014) (Figure 2.7).   
 
Figure 2.7: Anatomy of breast (www.webmd.com) 
In most of the cases BC originates from the cells covering the ducts of 
breast and is called ductal carcinoma. Cancer starting in the cells that surround the 
lobules is known as lobular cancer of breast. Rarely the cancer can start from rest 
of the breast tissue (cancer.org). Non-invasive cancers stay benign and do not 
spread beyond their site of initiation while the invasive cancers not only invade 
surrounding healthy but can also metastasize to distant organs of the (Figure 2.8) 
(www.iamstillawoman.com). Unfortunately, invasive BC occur more commonly. 
(breastcancer.org, 2014). BC can be classified into different types depending on 
the area from where the tumor starts primarily. The most common (80%) type of 
BC is the ductal carcinoma. About 12% cases are of lobular carcinoma while 
others like Mucinous carcinoma, tubular carcinoma, Paget‘s carcinoma and 
lymphoma occur rarely (8%) (Bocker, 2002).  
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Figure 2.8: Types of breast cancer (adapted from www.iamstillawoman.com)  
2.5 RISK FACTORS FOR BREAST CANCER 
Anything that affects a person’s chance of getting BC would be narrated as 
risk factor for BC. But risk factors do not elaborate all possible causes of the 
disease. Having one or more than one risk factors does not necessarily mean that a 
person will develop disease. A woman can develop BC in absence of any apparent 
risk factor or can remain healthy throughout her life even in the presence of one or 
more risk factors. Exact contribution of a specific risk factor is hard to know. What 
exactly is the cause of breast cancer is not completely known nevertheless, some 
factors are known to increase a person’s chance of getting BC. These factors are 
usually of genetic, socio-biological, environmental and physiological nature 
(Hunter, 2000).  
2.5.1 Non-Genetic Risk Factors 
Risk of breast carcinoma development increases with increase in age but 
the trend varies among ER-positive and ER-negative cases. Mostly women at 
postmenopausal stage tend to have ER-positive tumors (Yasui and Potter, 1999). 
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Both; early menarche (<12 years) and late menopause (>55 years) are BC risk 
factors. Probable reason of this effect corresponds to long term exposure of body to 
endogenous hormones (Kelsey et al., 1993). Delay of 2 years in regular menses 
leads to 10% risk reduction (Hsieh et al., 1990). Risk of BC is increased up to 3% 
by each year’s delay in the start of menopause (Trichopoulos et al., 1972). Women 
who bear first full-term pregnancy at younger age have reduced BC risk in future 
life (Macmahon et al., 1970). Parous women have lower risk of BC than nulli-
parous women (Lambe et al., 1994).  
Breast feeding is reported to reduce the risk of breast cancer. A large scale 
study done by Collaborative Group on Hormonal Factors in BC (2002) analyzed 
data of 47 epidemiological studies conducted in 30 countries, revealed risk 
reduction of 4.3% for every addition of 12 months of breast feeding. This reduction 
in risk corresponds to the reduction of a woman’s lifetime estrogen exposure due to 
ovulation suppression during breast feeding (Byers et al., 1985). Breast feeding 
also causes terminal differentiation of epithelial cells of breast tissue. 
Differentiated cells have longer cell cycle, thus have more time available for DNA 
repair and are indifferent to carcinogenic effects (Russo and Russo, 1994).  
Presence of more dense breast tissue (Kerlikowske et al., 2010), higher body 
mass index (BMI) (Zhu et al., 2005), diabetes mellitus (Noto et al., 2013), use of 
oral contraceptives (Hunter et al., 2010) and postmenopausal hormone 
replacement (HRT) (Kerlikowske et al., 2010) have also been reported to have an 
association with an increased risk of breast carcinoma. Socio-economic status, 
smoking and consanguineous marriage conferred to increase the risk of breast 
cancer (Asif et al., 2014). 
Lack of public awareness results in late diagnosis of BC; metastasized to 
other organs. Survival rate depends markedly on the stage of diagnosis. Detection 
at an early stage increases chances of treatment and the likelihood of up to 5 years 
survival is about 85% while five years survival rate at stage IV is just 10% (Gilani 
et al., 2003). Increase in survival rate of patients can be achieved by a significant 
approach of persuading awareness in population, better screening and early 
detection of breast cancer.  
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The breast self examination (BSE), clinical breast examination (CBE) and 
mammography are the recommended screening methods (Okobia et al., 2006). 
During BSE a woman can simply look and feel each of the breasts for presence of 
lump, swelling, distortion or any other significant change in the area of the breast. 
Physical examination performed by a health professional to identify changes in 
breast comes under the fold of CBE, while use of low energy X-ray with a higher 
sensitivity to detect presence of distinct masses and/or microcalcifications in 
human breast tissue is called mammography. BSE is a simple, inexpensive, easy 
and effective practice which can be carried out by the women themselves. It does 
neither require a professional expertise nor a visit to the hospital involving 
particular equipment. Regular performance of BSE can help in the  early detection 
of Breast cancer and thus increasing chances of early treatment and survival rate in 
women (Al-Naggar et al., 2011).  
2.5.2 Genetic Risk Factors 
Several genes are related to high risk of BC. Family history of breast cancer 
is one among well-documented risk factors. Presence of first degree relative with 
BC doubles the risk. Repair of breaks in DNA double-strand needs involvement of 
BRCA1 and BRCA2 (Chen et al., 1999). Mutations in these genes lead to 
incompletion of this role leading to tumor development (Murphy and Moynahan, 
2010). Presence of mutated BRCA1 and BRCA2 genes ascertain about 5% to 10% 
of all breast cancer cases. Their pattern of inheritance is autosomal-dominant 
(Evans et al., 2005). Deletion mutation in either gene can result in 10-fold 
enhanced risk of breast cancer development (Mavaddat et al., 2013). Carriers of 
Mutated BRCA1 and BRCA2 have about 65-85% and 40-85% risk of breast 
cancer respectively (Chen and Parmigiani, 2007; Evans et al., 2008). Mostly 
patients having mutated BRCA1 are triple negative, i.e. the tumor cells do not have 
estrogen receptors (ER), progesterone receptor (PR) and human epidermal growth 
factor receptor 2 (HER2) (Papelard et al., 2000). Presence of BRCA2 mutations is 
associated with sporadic cancers mostly expressing ER and PR involving just 16% 
triple negative cases (Mavaddat et al., 2012).  
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BC has a well known link with another high-penetrance gene; P53. Mutated 
P53 is related to Li-Fraumeni syndrome (LFS) which makes women more 
susceptible to breast cancer development. Mutation in another tumor suppressor 
gene; PTEN of MAPK/mTOR pathway results in PTEN hamartoma tumor 
syndrome/Cowden syndrome which significantly increases risk of breast cancer 
(Walsh and King, 2007). Mutation of PTEN is less prevalent but there is 85% life 
time BC risk for those who have germline PTEN mutations (Tan et al., 2012). 
Numerous low-penetrance genes are also reported to increase risk of BC. Mutated 
ATM, BRIP1, CHEK2, NBS1, PALB2, and RAD50 can lead to an increase of 2-4 
folds in breast cancer risk (Walsh and King, 2007). Further studies are being done 
to explicate more genes associated with breast cancer tumorigenesis.  
Keeping all the literature in view, this study was aimed to assess 
expressional and interactional analysis of IKKs in oncogenic cellular 
transformation and In Silico evaluation of potential nsSNPs in c-Myc protein. 
Furthermore, knowledge of early warning signs and potential risk factors of breast 
cancer in population was also among aims of study.  
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                                                                                   Chapter 3 
                 MATERIALS AND METHODS 
3.1 PREPRATION OF BUFFERS  
3.1.1 Phosphate Buffered Saline (PBS) 
PBS was prepared by dissolving 8 g NaCl, 1.44 g Na2HPO4 and 0.24 g 
KH2PO4 in 800 ml distilled water. The pH was adjusted to 7.4 using hydrochloric 
acid (HCl). Total volume was made up to 1 liter (1 L) by adding additional 
distilled water and buffer was sterilized by autoclaving.  
3.1.2 Radio Immunoprecipitation Assay (RIPA) Buffer  
RIPA buffer was prepared by mixing 150 mM Sodium chloride, 50 mM 
Tris (pH 8), 1.0% triton X100 and 0.5% Sodium dodecyl sulfat (SDS). 
3.1.3 Resolving Gel Solution  
10% resolving gel solution was prepared by mixing 4.8 ml water, 2.5 ml 
acrylamide/bis-acrylamide (37:1) solution (40%), 2.5 ml of 1.5M Tris base (pH 
8.8) and 100 μl SDS (10%). After that 100 μl freshly prepared 10% ammonia 
persulphate (APS) solution and 10 μl Tetra-ethylethylene-diamine (TEMED) was 
added to start polymerization (Table 3.1).  
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Table 3.1: Recipe of 10% resolving gel  
Water (ml) 3.6 4.8 7.2 
40% Gel solution (ml) 1.9 2.5 3.75 
Tris 1.5M (pH 8.8) 1.9 2.5 3.75 
10% SDS (μl) 75 100 150 
10% APS (μl) 75 100 150 
TEMED (μl) 7.5 10 15 
Total Volume 7.5 ml 10 ml 15 ml 
3.1.4 Stacking Gel Solution 
5ml stacking gel solution was prepared by mixing 3.645 ml water, 625 μl 
acrylamide/bis-acrylamide (37:1) mixture (40%), 630 μl of 1 M Tris base (pH 6.8) 
and 50 μl SDS (10%). After that 50 μl freshly prepared APS (10%) and 5 μl 
TEMED was added to start polymerization. 
Table 3.2: Recipe of stacking gel 
Water (ml) 2.185 3.645 5.84 
40% Acrylamide mixture (ml) 0.375 0.625 1 
Tris 1.5M (pH 6.8) 0.38 0.63 1 
10% SDS (μl) 30 50 80 
10% APS (μl) 30 50 80 
TEMED (μl) 3 5 8 
Total Volume 3 ml 5 ml 8 ml 
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3.1.5 SDS Transfer Buffer 
SDS transfer buffer was prepared by adding 2.9 g glycine (25 mM), 200 ml 
methanol, 5.8 g Tris base (50 mM), 0.4% SDS in water and pH was maintained at 
8.0. 
3.1.6 Assay Buffer  
Assay buffer was prepared by mixing 20 μl MgSO4 (20 mM), 200 μl 
adenosine triphosphate (ATP) (4 mM) and 780 μl Glacylglicine buffer (25 mM). 
The pH was adjusted to 7.8 using HCl. 
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3.2 PLASMID CONSTRUCTS 
Plasmids containing DNA; GFP (pEGFP-C1, Clontech) (Figure 3.1) , RFP 
(pDsRed2-C1, Clontech) (Figure 3.2), GFP tagged IKKα, GFP tagged IKKβ, GFP 
tagged truncated IKKα (HLH and LZ of IKKα was cut out using EcoRV and Sal I 
restriction enzymes (Fermentas, Leon-Rot, Germany), DsRed tagged c-My, c-Myc 
luciferase expression construct pMyc-TA-Luc (Clontech) (Figure 3.3) and 
constitutively expressing β-Galactosidase normalization construct pub6/V5-
His/lacZ (Invitrogen) (Figure 3.4) were used in this study. 
 
Figure 3.1: Restriction Map of pEGFP-C1 Vector. The IKKα and IKKβ cDNA, 
with signal sequence were separately cloned downstream of the cytomegalovirus 
(CMV) promoter in the expression vector pEGFP-C1. The origin of replication 
along with kanamycin/neomycin resistant genes, multiple cloning site (MCS) and 
unique restriction sites (bold) for some crucial restriction enzymes in the plasmid 
are shown. 
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Figure 3.2: Map of pDsRed2-C1 Vector. cDNA of the c-Myc gene, with signal 
sequence was cloned downstream of the cytomegalovirus (CMV) promoter in the 
expression vector pDsRed2-C1. The origin of replication along with 
kanamycin/neomycin resistant genes, multiple cloning site (MCS) and unique 
restriction sites for some crucial restriction enzymes in the plasmid are shown. 
 
 
Figure 3.3: Map of pMyc-TA-Luc Vector. The origin of replication along with 
ampicillin resistant gene, transcription blocker (TB), luciferase gene and unique 
restriction sites (bold) for some crucial restriction enzymes in the plasmid are 
shown.  
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Figure 3.4: Map of pub6/V5-His/lacZ Vector. The origin of replication along with 
ampicillin resistant gene, SV40 promoter and unique restriction sites for some 
crucial restriction enzymes in β-Galactosidase normalization construct pub6/V5-
His/lacZ are shown. 
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3.3 PRIMERS USED FOR qPCR 
The coding sequences of IKKα, IKKβ, c-Myc and GAPDH were taken 
from GenBank and one set of forward and reverse primers for each gene was 
developed using the Primer3 (http://frodo.wi.mit.edu/primer3/) software for qPCR 
(Table 3.3).  
Table 3.3: Primers for qPCR 
Gene  Primers  Annealing 
temperature 
Amplicon 
size (bp) 
IKKα Forward: 
5’-GAAGGTGCAGTAACCCCTCA-3’ 
58°C 169 
Reverse: 
5’-ATTGCCCTGTTCCTCATTTG-3’ 
57°C 
IKKβ Forward: 
5’-GCTGCAACTGATGCTGATGT-3’ 
58°C 157 
Reverse: 
5’-TGTCACAGGGTAGGTGTGGA-3’ 
59°C 
c-Myc Forward: 
5’-TCAAGAGGCGAACACACAAC-3’ 
58°C 110 
Reverse: 
5’-GGCCTTTTCATTGTTTTCCA-3’ 
57°C 
GAPDH Forward: 
5’-CCTGTTCGACAGTCAGCCG-3’ 
59°C 193 
Reverse: 
5’-CGACCAAATCCGTTGACTCC-3’ 
58°C 
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3.4 PLASMID DNA PREPARATION  
For plasmid containing DNA preparations the GeneJET Plasmid Midiprep 
Kit (Cat No: K0481, Thermoscientific, Lithuania) was used. 250 ml Erlenmeyer 
flasks containing 50 ml LB broth and appropriate selective antibiotics (ampicillin 
100 µg/ml or kanamycin 25 µg/ml) were inoculated with the desired transformed 
single colony of E. coli strain and incubated at 37°C with vigorous shaking at 200 
rpm in orbital shaker.  
The cells were harvested by centrifugation at 5000 g for 10 minutes in 
centrifuge (Biofuge Primo R, Thermo Scientific, Germany). The supernatant was 
discarded. The pelleted cells were resuspended in 2 ml of resuspension solution by 
vortexing with vortex mixer (Heidolph, Schwabach, Germany) and pipetting up 
and down until no cell clumps remained. 2 ml of lysis solution was added and 
mixed gently by inverting the tube 4-6 times until the solution became viscous and 
slightly clear. Then the solution was incubated for 3 minutes at room temperature. 
2 ml of the neutralization solution was added and mixed immediately by inverting 
the tubes 5-8 times. After it, 0.5 ml of the endotoxin binding reagent was added 
and mixed immediately by inverting the tubes 5-8 times and was incubated for 5 
min at room temperature.  
The mixture was centrifuged for 20 minutes at 20,000 rpm (48,000 g) to 
pellet cell debris and chromosomal DNA. After transferring the supernatant into a 
15 ml tube, 1 volume of 96% ethanol was added and mixed immediately by 
inverting the tube 5-6 times. Part of the sample (5.5 ml) was transferred to the 
supplied column pre-assembled with a collection tube (15 ml) and was centrifuged 
for 3 min at 2,000 g in a swinging bucket rotor. The flow-through was discarded 
and the column was placed back into the same collection tube. Remaining lysate 
was processed in the same way through the purification column. After that, 4 ml of 
Wash Solution I (diluted with isopropanol) was added to the purification column 
and was centrifuged for 2 minutes at 3,000 g in a swinging bucket rotor. The flow-
through was discarded and the column was placed back into the same collection 
tube.  
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Then 4 ml of Wash Solution II (diluted with ethanol) was added to the 
purification column and centrifuged for 2 minutes at 3,000 g in a swinging bucket 
rotor. The flow-through was discarded and the column was placed back into the 
same collection tube. Column wash was repeated with Wash Solution II. Then it 
was centrifuged for 5 min at 3,000 g in a swinging bucket rotor to remove residual 
wash solution. The collection tube containing the flow-through was discarded and 
the column was transferred into a fresh 15 ml collection tube (provided). Then 0.35 
ml elution buffer was added to the center of the purification column membrane and 
was incubated for 2 minutes at room temperature. Then it was centrifuged for 5 
min at 3,000 x g in a swinging bucket rotor to elute plasmid DNA.  
The purification column was discarded and the purified plasmid DNA was 
stored at -20°C. DNA was taken out by adding 250 µl elution buffer. Then 500 µl 
DNA precipitation solution was added in it and the mixture was kept on -20°C 
overnight. Next day, mixture was centrifuged at 1100 rpm for 15 mints at 4°C. 
Visible pellet of DNA was separated by throwing off the supernatant. 70% ethanol 
was added to the tube and was incubated at room temperature for 10 minutes. Tube 
was again centrifuged at 4°C for 7 minutes. Ethanol was thrown off and pellet was 
resuspended in 200 µl distilled water.  
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3.5 FLUORESCENT MICROSCOPY  
Fluorescence resonance energy transfer (FRET) analysis was carried out in 
order to find the interaction of IKKα and IKKβ with c-Myc protein using laser 
scanning microscope containing a photometrics coolsnap camera and suitable 
fluorescence filters controlled by Zeiss LSM 510 software. PixFRET plugin of 
ImageJ software was used to examine and analyze the interaction.  The graph was 
plotted to find mean FRET efficiency ± SEM (standard error of mean) of ten 
different cells for negative control and the cells indicating interaction.  
3.5.1 Cell Culture  
Immortalized, adherent human embryonic kidney (HEK 293) cells were 
cultured in complete Dulbecco’s modified Eagle’s medium (DMEM) containing 
10% fetal calf serum (FCS), penicillin (100 µg/ml), streptomycin (100 µg/ml), 
glutamine 2 mM. Cells were cultivated in 75 cm2 tissue culture flasks at 37°C, in a 
humidified (90%) and CO2 (5%) containing atmosphere. Cells were trypsinized 
and passaged every second or third day in proportion of 1:4 or 1:6, respectively. 
Passaging was done in laminar flow hood. For passaging the cell culture medium 
was removed, about 13 ml of PBS was used to wash the cells. PBS was removed 
completely and about 3 ml trypsin solution (37°C) was pipetted into the flask and 
spread evenly all over the bottom.  
Excessive trypsin was removed and the flask was placed in the incubator 
for 3 minutes. With an inverted microscope (Nikon TMS F 4X or 10X objective) it 
was checked if the cells were already detached and round in shape. Trypsinized 
cells were gently resuspended by several times up and down pipetting in 10 ml 
complete DMEM and 2 ml were transferred into a new tissue culture flask 
containing 13 ml of DMEM complete medium. Cells in tissue culture flasks were 
placed at 37°C in a humidified (90%) and CO2 (5%) containing atmosphere. 
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3.5.2 Cell Seeding on Cover Slip  
Cells were checked under inverted microscope (Nikon TMS F 4X or 10X 
objective) for confluency. Healthy, live, intact and about 90% confluent cells were 
subjected to passaging. Trypsinized cells were gently resuspended by several times 
up and down pipetting in 24 ml complete DMEM.  Sterile glass cover slip (15 mm) 
were again sterilized by washing with 70% ethanol and were kept to dry on tissue 
paper. One completely dry glass cover slip was placed in each well of 12 wells cell 
culture plate. Cells were resuspended gently by up and down pipetting and 2 ml 
medium with cells was dropped on each glass cover slip. Plate was rocked back 
and forth to assure equal distribution of cells over the glass cover slip. Plate was 
placed in humidified (90%) and CO2 (5%) containing incubator at 37°C.  
3.5.3 Transfection  
After 24 hours, at 70% confluence the cells were transfected. Transfection 
of GFP alone, RFP alone, GFP and RFP in combination as negative control, GFP-
IKKα, GFP-IKKβ, GFP-Trun. IKKα and DsRed-c-Myc was carried out using 
CaCl2 method. For each well, 36 µl of 1X Hepes Buffered Saline (HBS) was 
placed in a sterile tube. 2.1 µg respective DNA was added followed by addition of 
2.1 µl CaCl2 (2 M) to each tube and mixed immediately. After incubation for 20 
minutes at room temperature the transfection mixture was added in a drop wise 
fashion on surface of the cells in cell culture dish. Plate was rocked back and forth 
and was put in 5% CO2 incubator at 37°C for 24 hours. 
3.5.4 Live Cell Microscopy and Analysis  
Transfection of the cells was analyzed through detection of fluorescently labeled 
transfected cells under fluorescent microscope. An appropriate metallic chamber 
having a central hole of 13 mm was taken. Edges of the chamber hole were greased 
to hold the glass cover slips. Glass cover slip was fixed in metallic chamber taking 
care of the cells facing upwards. Cells were covered with 80 µl DMEM medium 
and a new plain glass cover slip was placed over the medium in metallic chamber. 
Glass cover slips were fixed carefully avoiding any bubble or leakage of the 
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medium. Chamber was fixed on stage and focus was adjusted for live cell 
fluorescent microscopy. FRET microscopy was carried out using laser scanning 
Zeiss Axiovert 135 microscope containing a photometrics coolsnap camera and 
suitable fluorescence filters controlled by Zeiss LSM 510 software. Images were 
acquired with 40X oil immersion objective using the 3-filter method. Fluorescence 
of GFP was imaged by exposing the cells to 10% intensity of the 488 nm argon 
laser beam for using bandpass emission filter (505–550 nm) while that of DsRed 
was acquired with 100% intensity of the 543 nm argon laser beam and the spectral 
detector set to longpass emission starting at 574 nm. All the images were acquired 
under exactly the same conditions. Calculation of spectral bleed through for the 
cells expressing only GFP or DsRed and determination of corrected FRET 
efficiency indicating physical interaction of candidate proteins was brought about 
using PixFRET plugin of ImageJ software. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3                                                                               Materials and Methods 
 38
3.6 QUANTITATIVE REAL TIME POLYMERASE CHAIN 
REACTION (qRT-PCR)  
3.6.1 Cell Culture and Transfection  
For qRT-PCR HEK 293 cells were cultured in 12 wells tissue culture plate. 
After one day transfection of 80% confluent cells was carried out. Plasmid DNA of 
IKKα, IKKβ, si-Myc, si-Myc control and c-Myc were transfected in triplicates 
using ExGen 500 (Cat: R0521, Roche, Germany). For each well, 2 µg of DNA was 
diluted in 100 µl of 150 mM NaCl. The mixture was vortexed gently and 
centrifuged briefly. Then 7.7 µl of ExGen 500 was added to the diluted DNA (not 
the reverse order) and the solution was vortexd immediately for 10 seconds. 
Mixture was then incubated for 10 minutes at room temperature. ExGen 500/DNA 
mixture was added slowly as drops to the cells in each well. The plate was gently 
rocked back and forth and from side to side to achieve even distribution of the 
complexes. After centrifugation at 280 g for 5 minutes the cell culture plate was 
placed in a CO2 incubator at 37°C for 24 hours. 
3.6.2 RNA Isolation 
After 48 hours transfection of the cells was confirmed by observing the 
cells under fluorescent microscope. Media was sucked out and the cell layer was 
rinsed with 1 ml ice cold PBS. To each well, 500 µl TRIZOL reagent was added to 
lyse the cells in cell culture plate. Cell lysate from each well was transferred to 
properly labeled 1.5 ml eppedorf tube. Tubes were centrifuged at 300 X g for 5 
minutes. Supernatant was removed and the pellet of cell lysate was resuspended in 
0.5 ml ice cold PBS. Tubes were incubated for 5 minutes at room temperature and 
centrifuged to remove the cell debris. The supernatant was transferred to new 1.5 
ml eppedorf tube. 
After addition of 150 µl chloroform to each tube, the tubes were vortexed 
vigorously for 15 seconds and were incubated at room temperature for 5 minutes. 
Tubes were centrifuged at 12,000 g for 15 minutes at 8°C. This centrifugation 
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resulted in distinguishable separation of the mixture into lower phase, middle 
interphase, and an upper colorless aqueous phase. The RNA was intact in the upper 
most aqueous phase. Therefore, upper phase was taken out very carefully avoiding 
the middle interphase and was transferred to the fresh eppedorf tube. To each tube, 
250 µl Isopropanol was added and incubated at 25oC for 10 minutes. Tubes were 
centrifuged at 11,000 g for 10 minutes at 4oC and the RNA pellet became visible at 
bottom of the eppedorf tube. The RNA pellet was washed with 70% ethanol and 
centrifuged at 7,000 g for 5 minutes at 4oC, three times. Tubes were left open to get 
air dry for 8 minutes and 100 µl diethylpyrocarbonate (DEPC) treated water was 
added to each pellet and RNA was mixed in it gently. 
3.6.3 cDNA Synthesis  
cDNA synthesis kit (Thermoscientific, Rockford, USA) was used to 
synthesize cDNA from template RNA. Kit components were mixed briefly after 
thawing. Template RNA was measured on nanodrop and 500 ng RNA from each 
sample was diluted in nuclease free water into a sterile PCR tube placed on ice. 
Then 1 µl random hexamer primer was added to the mixture and volume was made 
up to 12 µl. After that, 4 µl 5X reaction buffer, 1 µl RNase inhibitor (20 u/µl), 2 µl 
dNTP mixture (10 mM) and 1 µl reverse transcriptase (200 u/µl) was added to the 
mixture to make total volume of 20 µl.  
PCR mixture was gently mixed, centrifuged and placed in thermocycler 
(Applied Biosystem, Foster City, USA). The reaction mixture was incubated at 
42C for 60 minutes. Reverse transciption reaction was further processed for 25 
cycles through thermocycling conditions of 5 minutes at 25C for primers 
annealing and 80 seconds at 45C for extension. Reaction was terminated by 
heating at 70C for 10 minutes.  
3.6.4 qRT-PCR 
SYBR green PCR master mix (Applied biosystems, USA) was used for 
qRT-PCR. 1 µl of template cDNA, 1 µl (500nM) forward and 1 µl (500nM) 
reverse primer was added to each reaction mixture. Reaction was run on a StepOne 
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Plus machine (Applied Biosystems, Germany). Crossing threshold (Ct) points were 
calculated using StepOne Plus software while delta/delta-Ct method was used to 
calculate the relative expression of target genes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3                                                                               Materials and Methods 
 41
3.7 WESTERN BLOT ANALYSIS 
3.7.1 Cell Culture and Transfection  
HEK 293 cells were cultured in 6 well cell culture plate. After one day two 
wells of 70% confluent cells were left untreated, while each two wells were 
transfected with IKKα , mutant IKKα (inactive), c-Myc and IKKα+c-Myc together 
using X-tremeGENE 9 transfection reagent (Cat: 06365787001, Roche, Germany). 
Vial of X-tremeGENE 9 was brought to 25°C. After vortexing and mixing the 
transfection reagent was diluted with serum-free DMEM to a concentration of 3 µl 
reagent/100 µl medium for ratio of 3:1 in a sterile 1.5 ml eppendorf tube. Then 1 
µg DNA was added and gently mixed to 100 µl of diluted transfection reagent. 
Transfection reagent:DNA complex was incubated for 15 minutes at room 
temperature. Transfection complex was added to the cells in form of drops. Plate 
was gently swirled to ensure even distribution over the entire plate surface and was 
incubated in 5% CO2 incubator at 37
oC for 48 hours. Then one well each of 
untransfected cells, transfected with IKKα , mutant IKKα (inactive) and IKKα+c-
Myc were treated with Tumor necrosis factor α (TNFα) for half an hour prior to 
cell extract formation to stimulate expression and activity of IKKα. 
3.7.2 Cell Extract Preparation  
In order to prepare cytosolic cell extracts, 100 μl RIPA buffer and 1X 
protein inhibitor was added to each well. Plates were incubated for 1 minute to 
ensure effective lysis of the cells. Effective lysis of the plasma membrane was 
monitored with the help of inverse microscope under 10 X objective. After lysis 
the whole cell lysate from each well was taken in 1.5 ml eppendrof tube and 
centrifuged at 14000 g at -20°C for 20 minutes to eliminate the nuclei and parts of 
plasma membrane. The supernatant was shifted to fresh properly labeled 1.5 ml 
eppendrof tube.  
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3.7.3 Protein Quantification  
Cell extracts of each sample were diluted as 1:10 in distilled water. In a 96 
wells plate 200 µl of diluted Bradford reagent was pipetted out in each well. 1 µg/ 
µl bovine serum albumin (BSA) was dissolved in PBS. For the generation of BSA 
standard curve, 0 to 5 µg of BSA was pipetted into first 5 wells of 96 well plate. 
Then 1µl of diluted cell extract of each sample was added for quantification of 
protein to stay in the linear range. After 5 minutes incubation at room temperature 
the absorbance was measured at 595 nm with an Elisa reader (SLT Lab instruments 
340 ATTC). The standard curve of BSA was evaluated in MS Excel sheet. After 
analysis of linear regression the protein amount of each sample was quantified. 
3.7.4 SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
was also performed. 10 ml resolving gel mixture (Table 3.1) and 5 ml stacking gel 
mixture (Table 3.2) was prepared for preparation of 1 gel (6 cm x 9 cm x 0.015 
cm). The gel cast system (BioRad Mini Gel system, Germany) was filled with 
water to check its proper fitting. Then water was poured off and the separating gel 
solution was filled up to 5 cm height in gel cast.  A layer of isopropanol was 
pipetted on top to cover surface completely to prevent oxygen contact with gel 
solution. As the oxygen contact disables polymerization. Polymerization of 
resolving gel completed in 30 minutes, thus the layer of isopropanol was poured 
off and the stacking gel solution was immediately layered on top of the resolving 
gel. Comb (1 mm) was inserted carefully between glass plates avoiding bubbles 
and the gel was kept undisturbed for 30 minutes. 
Protein lysate of each sample containing 30 µg of protein was mixed with 
water to make the total volume up to 20 μl. Then 5 μl of 5X SDS sample buffer 
was added to each sample and cooked on 95 °C for 5 minutes and centrifuged at 
full speed for 2 minutes in a table top centrifuge machine. The gel sandwich was 
taken out of the gel cast and placed carefully in the electrophoresis tank. 1x SDS 
running buffer was filled in the inner and outer chamber of the tank and comb was 
Chapter 3                                                                               Materials and Methods 
 43
removed. Slots of the gel were cleansed with running buffer pipetting up and down 
few times to remove half-polymerized pieces of gel. 7 μl prestained protein marker 
and 25 μl of all the samples were loaded in the gel. Lid of gel tank was closed and 
the gel was allowed to run immediately to avoid diffusion of the loaded samples to 
surrounding area of the gel.  Electrophoresis parameter of power supply was firstly 
adjusted on 90 volts for 10 minutes so that proteins stage on border of the stacking 
gel and then on 140 volts for 1 hour. 
3.7.5 Wet Electrophoretic Gel Transfer  
Transfer of polyacrylamide gel to polyvinylidene fluoride (PVDF) 
membrane was carried out by wet electrophoretic transfer method. Equal sized 
piece of PVDF membrane, blotting sponge and 3MM whatman filter paper were 
cut. The blotting sponge and 3MM whatman filter paper were soaked in 1X SDS 
transfer buffer. The PVDF membrane was charged with 100% methanol for 3 
seconds. The blotting sandwich was built by placing one soaked blotting sponge 
lying immediately on blotting cassette then two soaked 3MM whatman filterpapers 
then the activated PVDF membrane, then gel then again two soaked 3MM 
whatman filterpapers and then again soaked blotting sponge. The blotting cassette 
(BioRad) was closed and positioned in the transfer chamber. Transfer was allowed 
to happen by adjusting the blotting parameters of power supply on 150 mA for 45 
minutes. 
3.7.6 Western Blot  
After 45 minutes the power supply was disconnected and PVDF membrane 
was taken out of the gel transfer sandwich. In order to block the unspecific binding 
sites, the PVDF membrane was incubated for 1 hour at 37 °C in blocking solution 
continuing gentle shaking. Blocking solution was prepared by mixing 5% fat free 
dried milk in PBST (PBS containing 0.1% Tween-20). The primary antibodies 
used in this study were, mouse monocolonal antibody against IKKα (B-8, Santa 
Cruz Biotechnology, Europe),  rabbit polycolonal IgG against p.H3 (Sc-8 Santa 
Cruz Biotechnology, Europe) and rabbit polyclonal antibody against Tubulin (H-
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235 Santa Cruz Biotechnology, Europe). A 50 ml falcon tube was taken to dilute 
concerning primary antibodies (1:500) in 5 ml antibody solution. After blocking 
step the membrane was shifted to the falcon tube containing primary antibody. 
Membrane was carefully placed to assure the protein side of membrane oriented 
towards the inner side to come in direct contact with antibody. Falcon tube was 
placed in rotor at 4°C for 24 hours.  
Next day, membrane was taken out of falcon tube and was rinsed 3 times 
with 1X PBST for 10 minutes. Secondary antibodies used in this study were anti-
mouse (Amersham biosciences, England) and secondary anti-rabbit (GE 
Healthcare UK). Concerning secondary antibody was diluted (1:1000) and 
membrane was shifted to the falcon. The falcon containing the membrane was 
placed in the rotor for 1 hour at room temperature. Chemiluminescence method 
was used to detect the immunoblotted proteins. Substrate solution and pierce super 
signal west pico solution was mixed in 1:1. Mixture was dropped on membrane 
and left undisturbed for 5 minutes.   
After incubation the membrane was placed in a plastic wrap carefully 
avoiding wrinkles of the plastic wrap. Excessive substrate solution was removed 
by with a tissue paper. For chemiluminescence detection the blot was exposed to 
BioMax film detection system (LumiImager, Roche, Germany). Images were 
captured and analyzed using ImageJ software.  
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3.8 LUCIFERASE REPORTER GENE ASSAY  
3.8.1 Cell Culture and Transfection  
  Cells of human prostate adenocarcinoma cell line (LNCaps) were cultured 
in 24 wells cell culture plate. Next day 70% confluent cells were transfected with 
respective DNA using X-tremeGENE 9 transfection reagent (Cat: 06365787001, 
Roche, Germany). A c-Myc Luciferase expression construct (pMyc-TA-Luc from 
Clontech) along with constitutively expressing β-Galactosidase normalization 
construct and various c-Myc, IKKα and IKKβ expression constructs were 
transfected to the cells in triplicates in 24 wells plate. Three wells of the cells were 
treated with 10 μM Bay11-7082 (Selleckchem, Germany) and three wells were 
treated with IKKβ inhibitor; 4 μM 2-[(aminocarbonyl) amino]-5-(4-fluorophenyl)-
3-thiophenecarboxamide (TPCA-1) (Selleckchem, Germany) for 12 hours prior to 
cell lysate formation. 
 
3.8.2 Cell Lysate formation 
After 48 hours of transfection media was completely sucked out and 50 μl 
lysis buffer was added to each well of 24 wells cell culture plate. Lysis buffer (pH 
7.8) contained 0.1M KH2PO4 buffer, 25 X protease inhibitor in ratio 25:1 and 
Triton-X 100 (0.1%). Plate was kept for incubation at 4°C for 20 minutes. Then the 
cell lysate was transferred from the wells to the 1.5 ml eppendorf tube. Samples 
were centrifuged on 14,000 rpm at 4°C for 20 minutes. The supernatant was 
carefully transferred to new properly labeled 1.5 ml eppendorf tube letting the 
pellet undisturbed. 
3.8.3 Luminometry 
Luminometry was performed to measure the luciferase activity. In each 
well of 96 well white plate 50 μl assay buffer was dropped. Then 20 μl of lysate 
was added to each well. Injection buffer was prepared by adding 750 μl luciferin (1 
mM) and 2250 μl Glacylglicine buffer (25 mM). 2.5 μl injection buffer was 
injected to each well in order to measure luciferase activity. Wallac 1420 
VICTOR2-Luminometer (Perkin Elmer, Vienna, Austria) was used to measure the 
light emission for 5 seconds.  
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3.8.4 Photometry for Beta Gal 
All the content from white 96 wells plate was transferred to the transparent 
96 well plate. 50 μl chlorophenol red-β-D-galactopyranoside (CPRG) was added to 
each well. Plate was incubated for half an hour at room temperature to develop 
color. To normalize b-galactosidase activity the samples were exposed to 590 nm 
colorimetric detection to measure the Beta GAL values after specific time interval. 
Readings were tabulated in MS word excel sheet and graphs were plotted using 
GraphPad Prism software.  
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3.9 IN SILICO EVALUATION OF EFFECTS OF CODING SNPS 
ON C-MYC  
3.9.1 Identification of SNPs in c-Myc 
Neucleotide and protein sequence in FASTA format were obtained from 
NCBI (http://www.ncbi.nlm.nih.gov). The longest isoform of c-Myc was selected 
for in silico analysis. In order to identify the SNPs related to longest isoform of 
human c-Myc proto onco-gene protein. Four public SNP databases named dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP), UniProt (http://www.uniprot.org), 
SNP500cancer (http://snp500cancer.nci.nih.gov/home.cfm) and GeneCards 
(http://www.genecards.org/) were used. Being in gene region, 165 SNPs were 
found to be related to c-Myc (gene ID: 4609, NCBI Reference Sequence: 
NP_002458.2). Out of 43 SNPs found in coding region of c-Myc, 27 non 
synonymous (nsSNPs) were kept into analytical consideration. 
3.9.2 Prediction of Tolerated and Deleterious SNPs and Functional 
Consequences of nsSNPs Using SIFT 
Sorting Intolerant from Tolerant (SIFT version 2) algorithm was used to 
predict probable effect of an amino acid substitution on protein function. SIFT is 
known to make a distinction between tolerated and deleterious amino acid changes 
in proteins (http://blocks.fhcrc.org/sift/SIFT.html). It is based on basic principle 
that substitution of some fundamentally conserved amino acids in a protein can 
have a potential influence on protein function and can be deleterious. 
Protein sequence in FASTA format was submitted as input to SIFT in order 
to predict possible effect of any probable amino acids substitution at every position 
of protein sequence. This investigation by FIST involved search for homologous 
sequences using TrEMBL 34.3 and SWISS-PORT version 51.3 databases. Then 
multiple alignments of available sequences were performed until a median 
sequence conservation score (MSCS) for the protein sequence approached 3.00. 
Tolerant and intolerant effect of nsSNPs of coding region was predicted as 
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tolerance index (TI) score which was normalized probability that the amino acid 
substitution is tolerated or not. It ranges from 0.0 to 1.0 while threshold for 
intolerance is ≤0.05. Deleterious predictions with median score of 3.25 or less were 
made with low confidence due to lack of sequence diversity for protein alignment. 
3.9.3 Prediction of Functional Consequences of nsSNPs Using PolyPhen 
 Polymorphism Phenotyping version 2 (PolyPhen-2) 
(http://genetics.bwh.harvard.edu) was used in order to predict detrimental outcome 
of nsSNPs on structural and functional basis. For each of the 27 variations in 
coding region of c-Myc protein, the position of SNP in protein sequence, wild type 
amino acid and present in protein and its substitute along with protein sequence 
were provided as an input to the algorithm.  
Homologs of the submitted sequence were searched using BLAST+ and 
aligned using MAFFT. Secator algorithm formerly executed in ClusPack software 
was used to gather reliably aligned sequences. Analyzed sequences and its 
homologes were taken into further consideration. PolyPhen also searched for 3D 
protein structures and contact information about amino acids in a number of 
structure based databases in order to firstly calculate the position-specific 
independent counts (PSIC) scores for allelic variants of SNP and then to evaluate 
its difference. On basis of all the information the effect of nsSNP on protein was 
predicted. Highly reliable score was predicted as ‘‘possibly damaging’’, an option 
of “may or may not”, meant that the nsSNP was ‘‘probably damaging’’ while 
being unlikely to phenotypic alteration in protein designated a nsSNP as 
‘‘benign’’.  
3.9.4 Prediction of Phenotypic Effects of nsSNPs Using SNPeffect 
  SNPeffect was used as a platform to forecast the molecular phenotypic 
influence of nsSNPs found in coding region of c-Myc protein. It worked beyond 
the scores got on conservational basis and mainly emphasizes to map the effect of 
SNPs on the capability of cells to uphold suitable concentration of the properly 
folded proteins in appropriate cellular region. For this evaluation, wild type protein 
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sequence in FASTA format and its variants were provided to the SNPeffect server 
(http://snpeffect.switchlab.org) as input. Homology threshold was adjusted to 90%. 
SNPeffect used TANGO which predicts the regions of protein sequence that are 
more prone to aggregation and measures the TANGO score with wild and variant 
amino acids. Effect of these variants on protein aggregation was evaluated on the 
basis of difference of the TANGO score (dTANGO).  
WALTZ server determined the aggregate morphology. dWALTZ score 
predicted amyloid-forming regions in protein sequence. Chaperone binding 
propensity was predicted by LIMBO for the Hsp70 chaperones and effect of 
variant was determined by dLIMBO score. SNPeffect did also use high resolution 
crystal structure of proteins from Protein Data Bank (PDB) and modeled the 
variants using the empirical force ﬁeld FoldX (version 2.5) to evaluate possible 
effects on stability and binding properties of the protein. 
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3.10 IMMUNOHISTOCHEMISTRY  
Protein expression of IKKα was evaluated in the tissue sections of IDC by 
Immunohistochemisrty (IHC). Scoring was categorized as low and high based on 
successive increase in percentage of positively stained cells for IKKα. 
3.10.1 Collection of Data and Samples  
Formalin fixed paraffin embedded (FFPE) tissue sections of 83 IDC 
patients were taken from oncology department of Sheikh Zayed Hospital, Rahim 
Yar Khan and Histopathology department of Armed Forces Institute of Pathology 
(AFIP), Rawalpindi, Pakistan. The hospitals kindly provided us with tissue 
sections of 4 µm in thickness along with the patient’s history about age, sex, 
metastasis, lymph node status and grade etc. from their registered record (Table 
3.4). 
Table 3.4: Clinicopathological features of Breast cancer patients 
Clinicopathological Features 
 
 Number of patients  
Age (n=74) 
≤ 50 37 
> 50 37 
Histological Grade (n=44) 
II 
35 
III 9 
Lymph node status (n=36) 
No metastasis 16 
Metastasis 20 
Progesterone Receptor (n=52) 
Positive 26 
Negative 26 
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3.10.2 Fixation 
 Slices of 4 µm thickness were cut from each FFPE tissue sample using a 
microtome. Thin slices were put onto glass slide and were passed through cold and 
hot water (70ºC) gradually. After the attachment of tissue to the glass slide, the 
slides were incubated on 55ºC for half an hour to get them heat fixed. 
3.10.3 Deparaffinization  
The glass slides containing samples were mounted on a plastic slide holder 
and were dipped in 100% Xylene for 15 minutes. Tissue samples were completely 
deparaffinized after removal of residual paraffin in this step. This step was 
repeated twice for complete deparaffinization. 
3.10.4 Rehydration 
For rehydration purpose the samples were subjected to ethanol solutions 
with gradually decreasing concentration. Samples were dipped firstly in 100% 
ethanol for 10 minutes, then 90% ethanol for 5 minutes, 70% ethanol for 5 
minutes, 50% ethanol for 5 minutes, 30% ethanol for 5 minutes and finally in 
water for 2 minutes. The tissue was clearly visible as white patch on the glass 
slides after this step. The tissue was precautiously kept wet to be safe from non 
specific staining in the background. 
3.10.5 Blocking 
In order to block the non specific binding of antibodies to the tissue, the samples 
were treated with mixture of 30% Hydrogen peroxide (H2O2) in water. The slides 
were placed on a water soaked tissue paper in covered tray to provide them moist 
environment. After 10 minutes incubation at room temperature the samples were 
washed with water to remove the blocking solution. 
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3.10.6 Primary Antibody Incubation 
The primary antibodies anti- IKKα (ab54628, abcam UK) was diluted to a 
1/50 concentration in 1% BSA. 1% BSA was prepared by dissolving 1 g of BSA in 
100 ml of 1X PBS.  Diluted primary antibody was applied to the tissue sample and 
was incubated at room temperature for 1 hour. 
3.10.7 Secondary Antibody Incubation 
In order to remove the primary antibody, the samples were subjected to 
wash by dipping the slides in autoclaved 1X PBS for 5 minutes. Horseradish 
peroxidase (HRP) labeled secondary antibody (ab47827, abcam, UK) was diluted 
to 1/500 in 1% BSA dissolved in 1X PBS. After entire removal of primary 
antibody, the diluted secondary antibody was applied to the tissue samples. The 
Samples were cautiously placed on wet tissue papers kept in a covered dark box 
for 1 hour at room temperature. 
3.10.8 Detection  
Diaminobenzidine (DAB) is characterized to impart an intense brown color 
to the HRP labeled proteins. A mixture of DAB substrate and chromogen was 
prepared using DAB Stainning Kit (Abcam Cat: ab64238, UK). This mixture was 
applied to the tissue samples and the samples were incubated for 10 minutes at 
room temperature. The stain was washed with tap water. Hemotoxylin was used to 
counterstain the nuclei of cells. The samples were then subjected to thorough 
washing in order to remove the hemotoxylin. Samples were air dried at room 
temperature and mounted with mounting media. Then cover slips were placed on 
the tissue.  
3.10.9 Visualization  
The 40 X and 100 X lens of Labomed TCM400 inverted microscope (Labo 
America Inc., USA) was used to visualize the staining of the slides. Images of 
stained sections of tissue samples were captured using ProgRes Capture Pro 2.6 
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(JENOPTIK Laser, Optik, Germany) and the images were ranked as low and high 
based on intensity of protein expression. 
3.10.10 Evaluation of Immunohistochemical Findings 
Slides were given to two histopathologist for their blind assessment of the 
stained tissue samples. Brown color staining in cytosol and dark blue in nuclear 
region was designated as positive staining. Positively stained cells were counted 
using 200X lens in 3 different fields for each sample.  
3.10.11 Statistical Analysis 
Statistical analysis was carried out using Statistical Package for the Social 
Sciences (SPSS), version 16.0 (Chicago, IL, USA). Spearman's Rank Order 
correlation was run to evalute the relationship between expression of the IKKα and 
different clinicopathological features of the patient.  Correlation with p<0.05 was 
taken to be statistically significant. 
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3.11 EVALUATION OF BREAST CANCER AWARENESS 
3.11.1 Study design 
A community based cross sectional descriptive analysis was carried out 
with the objective to assess the knowledge that young female students of the 
University possess regarding early warning signs and the risk factors involved in 
breast cancer. 
3.11.2 Study Area and Target Population  
The study was conducted in two major cities; Rahim Yar Khan and 
Bahawlpur of Southern Punjab, Pakistan. We involved female non medical 
students of Post Graduate Colleges in Rahim Yar Khan and Islamia University, 
Bahawalpur. While Medical students of Sheikh Zayed Medical College, Rahim 
Yar Khan and Quaid-e-Azam Medical College, Bahawalpur participated in this 
study. 
3.11.3 Sampling  
Sample selection was based on probability systematic random sampling 
method. An ample sample size was calculated using the Epi Info Program. 
Hypothesized proportion of outcome factors of the target population was 50%, 
absolute precision was 5%, confidence limit was 95%, and design effect was kept 
2. Appropriate sample size was calculated to be 316 non-medical and 235 medical 
students. After adding chance of 5% non-respondents the final sample size was of 
332 non-medical and 247 medical female students. Students with mild mental 
incapability or learning disability were not included in study population. Those 
students, who were not interested to answer, were not provided with questionnaire. 
Six questionnaires returned by non-medical students and seven from medical 
students presented insufficient information thus were excluded from the study. 
Final results were based on information provided by 326 non-medical and 240 
medical participants.  
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3.11.4 Instrument 
  The questionnaire was developed to assess basic awareness of early 
warning signs and risk factors of breast cancer among the female students of 
University. Experts were involved to ascertain the content validity of the 
questionnaire which consisted mainly of four sections. The first section included 
five questions about demographic characteristics of the students such as age, 
religion, ethnicity, marital status and residency of rural or urban area. The source 
of concerning knowledge was also asked from the participants.  
The second part of questionnaire comprised of five questions about basic 
knowledge of breast cancer. Third part included seven questions about the early 
warning signs and the fourth section consisted of twenty questions about the 
knowledge of breast cancer risk factors. Therefore 32 questions in total were 
included in the last three sections of the questionnaire. A score of 1 was awarded to 
the correct answer while 0 was given to the wrong answer. Thus, 32 was the 
maximum score one could achieve. The response of participants was grouped into 
“poor”, “insufficient”, “satisfactory” and “good” on the basis of obtained score of 
≤8, ≤16, ≤24 and ≤32 respectively.  
3.11.5 Statistical Analysis  
Students were classified as non-medical and medical group. Percentage and 
frequency distribution were calculated to demonstrate the categorical variables. 
Data was statistically analyzed, the results were tabulated and graphs were plotted 
using Graph Pad Prism Version 5 for Windows (San Diego, California USA). The 
Chi-Square test (x2) was performed to evaluate association between variables with 
a significance level set at p< 0.05.  
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Chapter 4 
RESULTS 
4.1 INTERACTION OF IKKs WITH c-MYC  
IKKs have been reported to enhance the stability of c-Myc protein 
suggesting a possible tumor promoting role. Although, as a known proto oncogene, 
c-Myc has been an intense area of research especially in relation to oncogenesis, 
but not much is known about the interaction between IKKs and c-Myc protein. 
Therefore, the first part of the study aims to investigate the physical interaction 
between IKKs and c-Myc protein.  
4.1.1 IKKα and IKKβ Interact with c-Myc  
In order to gain insight into the physical interactions between IKKs and c-
Myc protein, a live cell imaging technique- fluorescence resonance energy transfer 
(FRET) was employed in cell culture based system. It is the most effective way of 
analyzing the molecular interactions as it allows to measure small distances of 
around 1-10 nm in live cells. 
HEK-293 cells were transfected with fluorescently labeled IKKα (pEGFP-C1), 
IKKβ (pEGFP-C1) and c-Myc (pDsRed2-C1). FRET analysis revealed the 
interaction of DsRed tagged c-Myc, GFP tagged IKKα and IKKβ in nucleus and 
cytosol respectively (Figure 4.1). The graph was plotted to find mean FRET 
efficiency ± SEM (standard error of mean) of ten different cells for negative 
control and the cells indicating interaction (Figure 4.2).   
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Figure 4.1: Live cell imaging showing molecular interaction between IKKs and c-
Myc. Fluorescence resonance energy transfer (FRET) analysis was performed to 
visualize the interaction between fluorescently labeled IKKα, IKKβ and c-Myc in 
HEK-293 cells. From top to bottom, Lane 1-5; left to right 1) GFP mock 
transfected positive control cells, 2) DsRed mock transfected positive control cells, 
3) both GFP and DsRed mock transfected negative control cells, 4) GFP-IKKα and 
DsRed-c-Myc double transfected cells showing colocalization in nucleus of the 
cells, 5) GFP-IKKβ and DsRed-c-Myc double transfected cells showing 
colocalization in cytosol of the cells. Experiment was repeated three times and data 
was analyzed using ImageJ to calculate FRET efficiency. 
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Figure 4.2: Graphical representation depicting molecular interactions between 
IKKs and c-Myc in HEK 293 cells. The calculations were based on the FRET 
efficiencies measured through strength of fluorescent signals using PixFRET 
plugin of ImageJ software. Fluorescence intensities were normalized to control 
cells expressing only GFP and DsRed. Mean FRET efficiency ± SEM of ten 
representative cells of each category was calculated using GraphPad prism 
software. From Left to right; Negative control is the GFP and DsRed transfected 
cells showing no FRET signal, calculated FRET efficiency shows efficient 
interaction between IKKα and c-Myc and moderate association between IKKβ and 
c-Myc. 
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4.1.2 Interaction Domain of IKKα with c-Myc  
In order to find the interacting domain of IKKα with c-Myc, IKKα was 
deprived of helix loop helix (HLH) and leucine zipper (LZ) domains and was 
tagged with GFP. FRET analysis was carried out to find interaction of truncated 
IKKα with c-Myc using laser scanning microscope containing a photometrics 
coolsnap camera and suitable fluorescence filters controlled by Zeiss LSM 510 
software.  
Interaction of DsRed tagged c-Myc (pDsRed2-cMyc) with GFP tagged 
IKKα (pEGFP-IKKα), as well as GFP tagged truncated IKKα (pEGFP- IKKα 
ΔHLH-LZ) was clearly observed in nucleus. GFP-IKKα interaction was observed 
again as positive control while the interaction of GFP alone with c-Myc was used 
as negative control. No interaction of GFP tagged truncated IKKα with DsRed 
tagged c-Myc was observed, indicating the importance of HLH and LZ domains in 
the c-Myc and IKKα interaction (Figure 4.3). PixFRET plugin of ImageJ software 
was used to examine and analyze the interaction. Based on the results the graph 
was plotted to find mean FRET efficiency ± SEM of ten different cells for negative 
control and the cells indicating interaction (Figure 4.4).   
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Figure 4.3: Live cell imaging showing molecular interaction between IKKα and c-
Myc. Fluorescence resonance energy transfer (FRET) analysis was performed to 
visualize the interaction between fluorescently labeled IKKα, truncated IKKα 
IKKαΔHLH-LZ(the HLH and LZ loop was removed) and c-Myc in HEK-293 
cells. From top to bottom, Lane 1-5; 1) GFP mock trasfected positive control cells, 
2) DsRed-c-Myc trasfected positive control cells, 3) both GFP and DsRed mock 
trasfected negative control cells, 4) GFP-IKKα and DsRed-c-Myc double 
transfected cells showing colocalization in nucleus of the cells, 5) GFP-Trun.IKKα  
and DsRed-c-Myc double transfected cells showing no colocalization in the cells. 
Experiment was repeated three times and data was analyzed using ImageJ to 
calculate FRET efficiency. 
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Figure 4.4: Graphical representation depicting molecular interactions between 
IKKα, Trun.IKKα and c-Myc in HEK 293 cells. The calculations were based on 
the FRET efficiencies measured through strength of fluorescent signals using 
PixFRET plugin of ImageJ software. Fluorescence intensities were normalized to 
control cells expressing only GFP and DsRed. Mean FRET efficiency ± SEM of 
ten representative cells of each category was calculated using GraphPad prism 
software. From Left to right; Negative control is the GFP and DsRed transfected 
cells showing no FRET signal, calculated FRET efficiency shows efficient 
interaction between IKKα and c-Myc and no association between Trun.IKKα and 
c-Myc. 
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4.2 EFFECT OF IKKs AND c-Myc INTERACTION ON 
TRANSCRIPTIONAL EXPRESSION   
The FRET analysis was evident of the physical interaction between IKKs 
and c-Myc proteins in HEK 293 cells (Figure 4.1, 4.3), therefore it was intended to 
determine the functional relevance of IKKs and c-Myc interactions on each other 
at transcriptional level. In order to do so qRT-PCR was performed. 
 
4.2.1 No Effect of IKKs on c-Myc Transcription  
 
In order to determine the effect of IKKα or IKKβ overexpression on 
transcription of c-Myc, qRT-PCR was used. HEK 293 cells were transfected with 
fluorescent expressing plasmid constructs harbouring IKKα, IKKβ genes and gene 
silencing (si) constructs for c-Myc, si-Myc control and c-Myc in triplicates. 
Transfection efficiency was assessed by observing transfected cells under inverted 
fluorescent microscope. RNA was extracted manually and reverse transcribed 
using random hexamer primers to synthesize cDNAs. Housekeeping gene; 
GAPDH was used. SYBR green PCR master mix was used and crossing threshold 
(Ct) points were calculated using StepOne Plus software while delta/delta-Ct 
method was used to calculate the relative expression of target genes. No significant 
effect of IKK over expression on the transcriptional expression of c-Myc was 
observed (Figure 4.5). 
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Figure 4.5: Histogram showing effect of IKKα or IKKβ on transcription of c-Myc. 
q-PCR was performed with SYBR green detection to find effect of IKKα and 
IKKβ over expression on transcription of c-Myc mRNA. Expression was 
normalized taking GAPDH as a control. Mean of transcriptional expression ± SD 
was calculated. No significant effect of IKKα and IKKβ on transcription of c-Myc 
was noted.  
4.2.2 No Effect of c-Myc on Transcription of IKKα  
HEK 293 cells were transfected with c-Myc plasmid DNA in triplicates. 
Transfection efficiency was assessed by observing transfected cells under inverted 
fluorescent microscope.  qRT-PCR was carried out to determine the effect of c-
Myc overexpression on transcription of IKKα mRNA. RNA was extracted 
manually and reverse transcribed using random hexamer primers to synthesize 
cDNAs. Housekeeping gene was GAPDH. SYBR green PCR master mix was used 
and crossing threshold (Ct) points were calculated using StepOne Plus software 
while delta/delta-Ct method was used to calculate the relative expression of target 
genes. No significant effect was observed in transcriptional level of IKKα (Figure 
4.6). 
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Figure 4.6: Histogram showing no effect of c-Myc overexpression on 
transcriptional expression of IKKα gene. q-PCR was performed with SYBR green 
detection to find effect of c-Myc overexpression on transcription of IKKα. 
Expression was normalized taking GAPDH as a control. Mean of transcriptional 
expression ± SD was calculated. No significant effect of c-Myc overexpression on 
transcriptional expression of IKKα gene was noted.  
 
4.2.3 No Effect of c-Myc on transcription of IKKβ 
qRT-PCR was carried out to determine effect of  c-Myc over expression on 
transcription of IKKβ mRNA. HEK 293 cells were transfected with fluorescent 
expressing plasmid constructs harbouring DNA of c-Myc in triplicates. RNA was 
extracted by Trizol manual method and reverse transcribed using random hexamer 
primers to synthesize cDNAs. Housekeeping gene was GAPDH.  SYBR green 
PCR master mix was used and crossing threshold (Ct) points were calculated using 
StepOne Plus software while delta/delta-Ct method was used to calculate the 
relative expression of target genes. No significant effect was observed in 
transcriptional level of IKKβ (Figure 4.7) 
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Figure 4.7: Histogram showing no effect of c-Myc over expression on 
transcriptional expression of IKKβ gene. q-PCR was performed with SYBR green 
detection to find effect of c-Myc over expression on transcription of IKKβ mRNA. 
Expression was normalized taking GAPDH as a control. Mean of transcriptional 
expression ± SD was calculated. No significant effect of c-Myc over expression on 
transcriptional expression of IKKβ gene was noted.  
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4.3 EFFECT OF C-MYC ON IKKα EXPERESSION AND 
ACTIVITY  
c-Myc was found to have no effect on the  transcriptional expression of 
IKKα but the effect could also be on IKKα protein. Therefore, in order to analyze 
the possible effect of c-Myc on protein expression of IKKα, western blot analysis 
was performed.  
4.3.1 Effect of c-Myc on IKKα Protein Expression  
HEK 293 cells were treated with TNFα for half an hour to stimulate 
expression and activity of IKKα, in HEK293 cells transfected with pEGFP- IKKα), 
mutant IKKα-KD (kinase dead) and (pDsRed2- c-Myc). Samples were run on 10 
% SDS poly acrylamide gels and Western blot was performed using Mouse 
monocolonal primary antibody against IKKα (B-8, Santa Cruz Biotechnology, 
Europe) and secondary anti-mouse antibody (Amersham biosciences, England) 
was used to find protein expression of IKKα. c-Myc was not found to effect 
protein expression of IKKα (Figure 4.8). 
 
 
 
Figure 4.8: Western blot showing no effect of c-Myc on IKKα protein expression. 
SDS-PAGE and Western Blot was performed to evaluate effect of c-Myc over 
expression on expression of IKKα. HEK-293 cells were transfected with IKKα, 
Mutant IKKα (inactive) and c-Myc. Untransfected cells were treated with TNFα to 
stimulate expression and activity of IKKα. Blots were analyzed with ImageJ. c-
Myc seems to have no effect on IKKα expression. 
Chapter 4                                                                                                                     Results 
67 
 
4.3.2 Effect of c-Myc on IKKα Activity  
HEK 293 cells were treated with TNFα for half an hour to stimulate 
expression and activity of IKKα and were transfected with c-Myc (pDsRed2-
cMyc) with GFP tagged IKKα (pEGFP-IKKα). All the protein samples were run 
on 10 % SDS poly acrylamide gels and then were transferred to the Polyvinylidene 
fluoride (PVDF) membrane using wet electrophoretic transfer method. As Histone 
H3 is nuclear target of of IKKα thus Rabbit polycolonal IgG antibody against 
phosphorylated histone (p.H3) (Sc-8, Santa Cruz Biotechnology, Europe) and 
secondary anti-rabbit (GE Healthcare UK) antibodies were used to find effect of c-
Myc protein on nuclear activity of IKKα. c-Myc was not found to effect activity of 
IKKα (Figure 4.9). 
 
Figure 4.9: Western blot showing no effect of c-Myc over expression on IKKα 
activity. SDS-PAGE and Western Blot was performed after transfection of HEK-
293 cells with IKKα and c-Myc. Untreated cells and the cells transfected with 
IKKα alone were treated with TNFα for half an hour to stimulate expression and 
activity of IKKα. Blots were analyzed with ImageJ. c-Myc seems to have no effect 
on nuclear activity of IKKα. 
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4.4 EFFECT OF IKKs ON TRANSCRIPTIONAL ACTIVITY OF 
c-MYC  
c-Myc was found to have no effect on the  translational expression and 
activity of IKKα. As c-Myc is a transcription factor thus IKKs may affect the 
transcriptional activity of c-Myc. Luciferase assay was performed in order to 
analyze the possible effect of IKKs on transcriptional activity of c-Myc. 
 
4.4.1 IKKα Reduces Transcriptional Activity of c-Myc 
A Myc luciferase expression construct Myc-luc (pMyc-TA-Luc) along with 
constitutively expressing β-Galactosidase normalization construct, IKKα (pEGFP-
C1), and c-Myc (pDsRed2-C1) expression constructs were transfected to human 
prostate adenocarcinoma cell line (LNCaps) in triplicates. Basal expression of c-
Myc is less in LNCaps as compared to HEK-293 cells thus LNCaps was used to 
perform this experiment. Luciferase activity was measured by use of luminometer. 
IKKα was found to reduce the transcriptional activity of c-Myc (Figure 4.10). Cells 
were also treated with inhibitor of IKK i.e. 10 μM Bay11-7082 for 12 hours (Yeh 
et al., 2011) in order to confirm the results. Increase in the transcriptional activity 
of c-Myc in presence of inhibitors confirmed that IKKα is responsible for indicated 
reduction (Figure 4.11). 
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Figure 4.10: Histogram showing reduced c-Myc transcriptional activity due to 
IKKα. LNCap cells were transfected with c-Myc luciferase reporter, c-Myc and 
IKKα. Luciferase activity was normalized to constitutive β-Galactosidase 
expression. Standard deviation (SD) was used for descriptive error bars.  
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Figure 4.11: Histogram showing decrease in the IKKα caused reduction of c-Myc 
transcriptional activity by inhibitors of IKKα. LNCap cells were transfected with c-
Myc luciferase reporter, c-Myc and IKKα. Cells were stimulated with TNF alpha. 
Luciferase activity was normalized to constitutive β-Galactosidase expression. 
Cells treated with 10 μM Bay11-7082 for 12 hours show significant increase in 
transcriptional activity of c-Myc. Standard deviation (SD) was used for descriptive 
error bars. 
 
4.4.2 IKKβ Reduces Transcriptional Activity of c-Myc 
A Myc luciferase expression construct Myc-luc (pMyc-TA-Luc) along with 
constitutively expressing β-Galactosidase normalization construct, c-Myc 
(pDsRed2-C1) and constitutively active IKKβ (Ca-IKKβ) (pEGFP-C1) expression 
constructs were transfected to LNCaps in triplicates. Luciferase activity was 
measured by use of luminometer. IKKβ was found to reduce the transcriptional 
activity of c-Myc (Figure 4.12).  Cells were also treated with IKK inhibitor; 10 μM 
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Bay11-7082 (Yeh et al., 2011) for 12 hours and potent IKKβ inhibitor; 4 μM 
TPCA-1 for 12 hours in order to confirm the results. Increase in the transcriptional 
activity of c-Myc in the presence of inhibitors confirmed that IKKβ to be 
responsible for indicated reduction (Figure 4.13). 
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Figure 4.12: Histogram showing reduced c-Myc transcriptional activity due to 
IKKβ. LNCap cells were transfected with c-Myc luciferase reporter, c-Myc and 
constitutively active IKKβ (Ca-IKKβ). Luciferase activity was normalized to 
constitutive β-Galactosidase expression. Standard deviation (SD) was used for 
descriptive error bars. 
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Figure 4.13: Histogram showing decrease in the IKKβ caused reduction of c-Myc 
transcriptional activity by inhibitors of IKKβ. LNCap cells were transfected with c-
Myc luciferase reporter, c-Myc and constitutively active IKKβ. Luciferase activity 
was normalized to constitutive β-Galactosidase expression. Cells treated with 10 
μM Bay11-7082 for 12 hours and potent IKKβ inhibitor; 4 μM TPCA-1 for 12 
hours show significant increase in transcriptional activity of c-Myc. Standard 
deviation (SD) was used for descriptive error bars. 
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4.5 IN SILICO ANALYSIS OF CODING SNPs AND THEIR 
EFFECT ON C-MYC PROTEIN   
c-Myc is actively involved in the regulation of a variety of genes related to 
cancer development and persistence (Gustafson and Weiss, 2010). Disease risk and 
progression is commonly influenced by the existing polymorphisms in the genome. 
The most frequent type of polymorphisms found in human genome is SNP (Noreen 
et al., 2012). Studying the structural and functional effect of the nsSNPs on the 
protein can help in the selection of functionally important SNPs. Some sequence 
and structural homology based algorithms were used to find those nsSNPs which 
can play potential role in structural and functional alteration of c-Myc proto-
oncoprotein. 
4.5.1 Dataset compilation  
Total 165 human c-Myc SNPs from the dbSNP database were further 
scrutinized. GeneCards database included four additional pathologically important 
SNPs of c-Myc2 proto oncogene reported in Burkitt lymphoma samples; 
VAR_063384 (Glu39Asp), VAR_063385 (Pro57Ser), VAR_063386 and 
VAR_063387 (Asn86Thr). The non-conding region of gene was found to contain 
122 SNPs out of which 38 (23%) were in the region of 5’ near gene, 13 (8%) were 
in 5’ UTR, 51 (31%) were in intronic region, 11 (7%) were in 3’ UTR and 9 (5%) 
were in region of 3’ near gene. Coding region harbored 43 SNPs out of which 29 
(17%) were non-synonymous and 14 (9%) were synonymous (Figure 4.14).  
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Figure 4.14: Pi chart showing distribution of SNPs in human c-Myc gene region  
 
4.5.2 Non-synonymous SNPs of c-Myc Gene  
Non-synonymous SNPs of c-Myc gene were supposed to be of more importance as 
their variants can directly affect protein structure and function. Detailed 
information about all nsSNPs of coding region included their dbSNPid, 
chromosomal position, mRNA position, dbSNP allele, codon position and amino 
acid position (Table 4.1). The significant domains and position of phosphorylation, 
ubiquitination and location of nsSNPs (predicted to be damaging by SIFT, 
PolyPhen or SNPeffect algorithms) in c-Myc1 protein are indicated in Figure 4.15. 
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Table 4.1: nsSNPs of c-Myc coding region 
dbSNP id Chromosome 
Position 
mRNA 
Position 
dbSNP 
Allele 
Codon 
Position 
Amino Acid  
Position 
rs139294902 128750498 560 C/G 2 12 
rs146505192 128750527 589 T/C 1 22 
rs148915481 128750534 596 A/G 2 24 
rs4645959 128750540 602 A/ G 2 26 
rs114570780 128750602 664 T/C 1 47 
rs148228388 128750735 797 C/A 2 91 
rs199561469 128750773 835 G/C 1 104 
rs150308400 128750906 968 G/A 2 148 
rs137906262 128750938 1000 C/A 1 159 
rs61755060 128750967 1029 G/T 3 168 
rs147329312 128750977 1039 A/C 1 172 
rs4645960 128750986 1048 G/T 1 175 
rs4645960 128750986 1048 G/C 1 175 
rs4645961 128751016 1078 G/A 1 185 
rs112602073 128751121 1183 C/T 1 220 
rs147506213 128751160 1222 C/A 1 233 
rs186663828 128751185 1247 C/T 2 241 
rs148544254 128751200 1262 C/T 2 246 
rs150629172 128752729 1415 C/A 2 297 
rs139697494 128752745 1431 C/A 3 302 
rs146971340 128752799 1485 T/A 3 320 
rs4645968 128752849 1535 C/T 2 337 
rs200431478 128752924 1610 C/T 2 362 
rs141095253 128753029 1715 C/T 2 397 
rs145561065 128753141 1827 G/C 3 434 
rs148863193 128753155 1841 G/T 2 439 
rs201337668 128753196 1882 T/G 1 453 
rs143501729 128753200 1886 C/A 2 454 
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Figure 4.15: Schematic diagram of the significant domains and position of 
phosphorylation, ubiquitination and nsSNPs in c-Myc protein. It details the 
location of highly conserved Myc homology boxes (MBI, MBII, MBIII and 
MBIV), basic region (BR), helix-loop-helix (HLH) and leucine zipper (LZ) 
domains. The numbers below represent the amino acid that borders each 
significant domain of protein. Specific N-terminal features, including the location 
of phosphorylation and ubiquitination (lysine residues) are indicated on upper side 
while location of nsSNPs (predicted to be damaging by SIFT, PolyPhen or 
SNPeffect algorithms) are indicated below. 
 
4.5.3 Prediction of Tolerated and Deleterious SNPs and Functional 
Consequences of nsSNPs Using SIFT 
The SIFT program predicts the tolerant or deleterious effect of amino acid 
change on protein function. The analysis mainly considers the alignment of 
homologous sequences, physical properties of amino acids and the effect of natural 
nonsynonymous polymorphisms on phenotypic alterations by aligning paralogous 
and orthologous protein sequences. The prediction of possible substitutions for 
positions 1-454 amino acids was also done. Possible substitutions for those nsSNPs 
are shown in Figure 4.16 which were predicted to have some damaging effect by 
SIFT, PolyPhen or SNPeffect algorithms. ‘Seq-Rep’ is actually the fraction of 
sequences that has one of the fundamental amino acids. Low fraction shows that 
the position is unalienable or is severely gapped providing little information which 
results in poor prediction. Amino acids are shown in color codes i.e. basic 
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(red), acidic (blue) non polar (black); uncharged polar (green). Capital letters 
signifies the amino acids which come into view during the alignment while lower 
case letters are the consequence of prediction (Figure 4.16).  
Out of these eight nsSNPs, rs139294902 (Pro12Arg), rs4645959 
(Asn26Ser), rs114570780 (Tyr47His), rs150308400 (Cys148Tyr) and rs137906262 
(Leu159Ile) are located within N-terminal trans-activation domain while 
rs145561065 (Leu434Phe) and rs143501729 (Ala454Glu) harbor the C-terminal 
domain of c-Myc1 protein (Figure 4.15). Sequence homology-based tool of SIFT 
was used to predict tolerant and deleterious effect of 27 nsSNPs present in coding 
region of MYC proto onco-gene protein. As a result 8 nsSNPs were found to be 
deleterious in total, out of which 2 had low confidence due to median score >3.25 
(Table 4.2, Figure 4.17). Out of these eight nsSNPs, rs139294902 (Pro12Arg), 
rs4645959 (Asn26Ser), rs114570780 (Tyr47His), rs150308400 (Cys148Tyr) and 
rs137906262 (Leu159Ile) are located within N-terminal trans-activation domain 
while rs145561065 (Leu434Phe) and rs143501729 (Ala454Glu) harbor the C-
terminal domain of c-Myc1 protein (Figure 4.15). 
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Figure 4.16: Prediction of possible substitutions of amino acids in human c-Myc1 
protein using SIFT algorithm. Amino acids are shown in color code: basic 
(red), acidic (blue) non polar (black); uncharged polar (green). Capital letters 
signify amino acids which come into view during the alignment while lower case 
letters are the consequence of prediction. ‘Seq-Rep’ is actually the fraction of 
sequences that have one of the fundamental amino acids. Low fraction shows that 
position is unalienable or is severely gapped providing little information which 
results in poor prediction.  
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Table 4.2: SIFT analysis of nsSNPs in coding region of human c-Myc proto 
oncogene protein  
dbSNP id Amino Acid Variant SIFT Prediction Tolerance Index 
rs139294902 Pro [P]/Arg [R] Intolerant * 0.00 
rs146505192 Phe [F]/Leu [L] Tolerant 1.00 
rs148915481 Asn [N]/Ser [S] Tolerant 0.99 
rs4645959 Asn [N]/Ser [S] Intolerant 0.01 
rs114570780 Tyr [Y]/His [H] Intolerant 0.00 
rs148228388 Ala [A]/Glu [E] Tolerant 0.06 
rs199561469 Gly [G]/Arg [R] Tolerant 0.36 
rs150308400 Cys [C]/Tyr [Y] Intolerant 0.00 
rs137906262 Leu [L]/Ile [I] Intolerant 0.02 
rs61755060 Gln [Q]/His [H] Tolerant 0.45 
rs147329312 Lys [K]/Gln [Q] Tolerant 0.11 
rs4645960 Gly [G]/Cys [C] Tolerant 0.12 
rs4645960 Gly [G]/Arg [R] Tolerant 0.13 
rs4645961 Val [V]/Ile [I] Tolerant 0.26 
rs112602073 Pro [P]/Ser [S] Tolerant 0.93 
rs147506213 Pro [P]/Thr [T] Tolerant 0.64 
rs186663828 Ser [S]/Leu [L] Tolerant 0.19 
rs148544254 Pro [P]/Leu [L] Tolerant 0.26 
rs150629172 Pro [P]/His [H] Tolerant 0.15 
rs139697494 His [H]/Gln [Q] Tolerant 0.15 
rs146971340 His [H]/Gln [Q] Tolerant 0.74 
rs4645968 Ala [A]/Val [V] Tolerant 1.00 
rs200431478 Ser [S]/Phe [F] Intolerant 0.01 
rs141095253 Pro [P]/Leu [L] Tolerant 0.05 
rs145561065 Leu [L]/Phe [F] Intolerant 0.01 
rs148863193 Arg [R]/Leu [L] Tolerant 0.12 
rs201337668 Cys [C]/Gly [G] Tolerant 0.64 
rs143501729 Ala [A]/Glu [E] Intolerant *  0.00 
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Note: Variants with tolerance index ≤0.05 score are considered as deleterious 
while others are taken to be tolerant.  
* Predictions are made with low confidence because MSCS > 3.25, thus the 
interpretations should be made cautiously. 
 
4.5.4 Prediction of Functional Consequences of nsSNPs Using PolyPhen 
PolyPhen-2 server was used to predict structural and functional effects of 
27 nsSNPs reported in the coding region of c-Myc proto oncogene protein. Using 
structure and sequence based predictive features PolyPhen searched for 
homologous protein sequences for multiple alignment and 3D protein structures to 
find probability score and predicted possible influence of variants on the protein. 
Out of 27 mutations, 7 were predicted to be probably damaging with probabilistic 
scores above 0.85, one variant was forecasted to be possibly damaging with 
probabilistic score above 0.15 while all others were considered to be benign (Table 
4.3 Figure 4.17). Out of these eight nsSNPs, rs114570780 (Tyr47His), 
rs148228388 (Ala91Glu), rs199561469 (Gly104Arg), rs150308400 (Cys148Tyr), 
rs137906262 (Leu159Ile) are located within N-terminal trans-activation domain 
while rs200431478 (Ser362Phe), rs141095253 (Pro397Leu) harbor the C-terminal 
domain of c-Myc1 protein (Figure 4.15). 
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Figure 4.17: nsSNPs of human c-Myc1 protein predicted by SIFT, PolyPhen and 
SNPeffect algorithms to have some biological importance  
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Table 4.3: Polyphen analysis of nsSNPs in coding region of human c-Myc proto 
oncogene protein 
dbSNP id Amino Acid Variant PolyPhen  Prediction Polyphen Score 
rs139294902 Pro [P]/Arg [R] Benign 0.027 
rs146505192 Phe [F]/Leu [L] Benign 0.008  
rs148915481 Asn [N]/Ser [S] Benign 0.007 
rs4645959 Asn [N]/Ser [S] Benign 0.160 
rs114570780 Tyr [Y]/His [H] Probably Damaging 0.955 
rs148228388 Ala [A]/Glu [E] Possibly damaging  0.452 
rs199561469 Gly [G]/Arg [R] Probably Damaging 0.915 
rs150308400 Cys [C]/Tyr [Y] Probably Damaging 0.999 
rs137906262 Leu [L]/Ile [I] Probably Damaging 0.997 
rs61755060 Gln [Q]/His [H] Benign 0.155 
rs147329312 Lys [K]/Gln [Q] Probably Damaging 0.971 
rs4645960 Gly [G]/Cys [C] Benign 0.048 
rs4645960 Gly [G]/Arg [R] Benign 0.269 
rs4645961 Val [V]/Ile [I] Benign 0.248 
rs112602073 Pro [P]/Ser [S] Benign 0.135 
rs147506213 Pro [P]/Thr [T] Benign 0.002 
rs186663828 Ser [S]/Leu [L] Benign 0.270 
rs148544254 Pro [P]/Leu [L] Benign 0.273 
rs150629172 Pro [P]/His [H] Benign 0.001 
rs139697494 His [H]/Gln [Q] Benign 0.041 
rs146971340 His [H]/Gln [Q] Benign 0.327 
rs4645968 Ala [A]/Val [V] Benign 0.009 
rs200431478 Ser [S]/Phe [F] Probably Damaging 0.914 
rs141095253 Pro [P]/Leu [L] Probably Damaging 0.999 
rs145561065 Leu [L]/Phe [F] Benign 0.100 
rs148863193 Arg [R]/Leu [L] Benign 0.193 
rs201337668 Cys [C]/Gly [G] Benign 0.00 
rs143501729 Ala [A]/Glu [E] Benign 0.014 
Chapter 4                                                                                                                     Results 
83 
 
Note: Variations with probabilistic score above 0.85 and 0.15 are considered to be 
“Probably damaging” and “possibly damaging” respectively while all the resting 
are categorized to be “Benign”. 
 
4.5.5 Prediction of Molecular Phenotypic Effects of nsSNPs Using SNPeffect 
SNPeffect server was used to predict the effect of molecular phenotype of 
nsSNPs present in coding region of c-Myc protein. dTANGO, dWALTZ and 
dLIMBO scores were calculated to find effect of 27 nsSNPs on aggregation 
tendency, amyloid propensity and chaperone binding tendency respectively. 
Threshold for some significant effect was ranging from -50 to 50.  
The dLIMBO score for Pro/Leu variation at position 397 (rs141095253) 
equals -277.70, which means that the mutation decreases the chaperone binding 
tendency of c-Myc protein. The scores for rest of the variants were not observed to 
be more than 50 or less than -50. The result shows that none of these nsSNPs other 
than rs141095253 is able to bring significant change in the aggregation tendency, 
amyloid propensity and chaperone binding tendency of c-Myc protein (Table 4.4). 
The difference in free energy of the mutation was calculated using empirical 
protein design force field (FoldX). The submitted sequence had 98.80 percent 
homology with 1nkp. Using FoldX a homology model was built starting from this 
PDB. The difference in free energy due to Pro/Leu variation at position 397 was of 
2.68 Kcal/mol. This entails that the mutation reduces the protein stability (Figure 
4.18). For rest of the variations SNPeffect could not predict possible changes in the 
stability of protein which could have been brought by variants due to the 
unavailability of adequate structural information of c-Myc in the form of PDB 
model.  
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Figure 4.18: Molecular visualization of the wild type; Pro (left) and variant; Leu 
(right) residues colored in red at position 397 in c-Myc protein.  
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Table 4.4: SNPeffect analysis of nsSNPs in coding region of human c-Myc proto 
oncogene protein  
dbSNP id dTANGO Agg.  
Tend. 
dWALTZ Amyl. 
Prop. 
dLIMBO Chap. 
Bind. 
Tend. 
rs139294902 0.38 No effect -0.05 No effect 0.00 No effect 
rs146505192 -1.21 No effect -0.93 No effect 0.00 No effect 
rs148915481 -0.01 No effect -0.36 No effect 0.00 No effect 
rs4645959 0.00 No effect -0.06 No effect 0.00 No effect 
rs114570780 0.04 No effect -10.16 No effect 0.00 No effect 
rs148228388 -14.97 No effect 0.00 No effect 0.00 No effect 
rs199561469 0.41 No effect -0.05 No effect 0.00 No effect 
rs150308400 9.73 No effect 0.24 No effect 0.00 No effect 
rs137906262 0.00 No effect 8.63 No effect 0.00 No effect 
rs61755060 0.04 No effect -0.28 No effect 0.00 No effect 
rs147329312 -0.41 No effect 0.05 No effect 0.00 No effect 
rs4645960 0.00 No effect 0.00 No effect 0.00 No effect 
rs4645960 0.41 No effect -0.05 No effect 0.00 No effect 
rs4645961 0.00 No effect -0.00 No effect 0.00 No effect 
rs112602073 0.00 No effect 0.00 No effect 0.00 No effect 
rs147506213 0.00 No effect 0.07 No effect 0.00 No effect 
rs186663828 0.00 No effect 0.04 No effect 0.00 No effect 
rs148544254 0.00 No effect 0.00 No effect 0.00 No effect 
rs150629172 0.04 No effect -0.00 No effect 0.00 No effect 
rs139697494 -0.05 No effect 0.01 No effect 0.00 No effect 
rs146971340 -0.05 No effect 1.21 No effect 0.00 No effect 
rs4645968 0.00 No effect 0.00 No effect 0.00 No effect 
rs200431478 0.00 No effect 0.00 No effect 0.00 No effect 
rs141095253 1.17 No effect 0.06 No effect -277.70 Decrease 
rs145561065 0.00 No effect 0.16 No effect -0.05 No effect 
rs148863193 -0.68 No effect -0.02 No effect 0.02 No effect 
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rs201337668 0.00 No effect -0.00 No effect 0.00 No effect 
rs143501729 0.00 No effect 0.00 No effect 0.00 No effect 
 
Note: Variations with dTANGO, dWALTZ and dLIMBO between -50 and 50 are 
supposed to have no affect on aggregation tendency, amyloid propensity and 
chaperone binding tendency respectively. Agg. Tend. = Aggregation Tendency, 
Amyl. Prop. = Amyloid Propensity and Chap. Bind. Tend. = Chaperone Binding 
Tendency. 
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4.6 ASSOCIATION OF IKKα EXPRESSION WITH 
CLINICOPATHOLOGICAL FEATURES OF BC PATIENTS 
IKKα has been reported to play pro-tumorogenic as well as anti-
tumorogenic role. To explore the molecular details and ultimate role of IKKα one 
of the objectives included the expressional analysis of IKKα in breast cancer tissue 
samples and its correlation to clinicopathological features of Pakistani BC patients. 
In 83 IDC tissue samples, IKKα expression was analyzed. Results of 9 samples 
were not predictable probably due to improper formalin fixation thus were 
excluded from the study. 74 remaining samples included 37 patients aged ≤50 
years while 37 were of >50 years. 26 samples with PR positive status and 26 with 
PR negative status were stained and analyzed (Table 4.5).  
IKKα expression was categorized as low or high depending on percentage 
of IKKα positive cells in IDC tissue samples (Figure 4.19) Analyses was 
performed using the SPSS software program (SPSS Standard version 16.0, 
Chicago, IL). Comparison of the IKKα expressions in breast cancer tissues was 
performed using paired t-test analysis for the clinicopathological feature having 
equal number of tissue samples in both groups to be compared, while for the 
unequal number of samples correlation was analyzed through spearman test. The p 
value <0.05 was considered significant. 
Histological grade directly affects the propensity to invasion and metastasis 
of breast cancer. Low grade tumors morphologically resemble normal cells and are 
well differentiated while high grade tumors are highly undifferentiated. Highly 
undifferentiated cells are more likely to invade surrounding organs of the body 
causing metastasis and poor prognosis (cancer.gov, 2014). Total 35 samples were 
of grade II and 9 of grade III. Low expressional level of IKKα was observed in 14 
of grade II and 4 of grade III tissue samples. However, no significant correlation 
(p=0.814) between IKKα expression and histological grade was observed (Table 
4.5).  
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Metastasis is the hall mark of breast cancer. A cancer escapes the immune 
surveillance by invading the lymph and blood vessels gaining ability to metastasize 
at distant organs of the body. 20 samples were positive for lymph node metastasis 
while 16 were non metastatic samples. Low expression of IKKα was observed in 5 
samples with no lymph node metastasis and 10 metastatic samples. While high 
expression was observed in 10 metastatic and 11 non metastatic samples.  
Although no significant correlation (p=0.270) between IKKα expression and 
lymph node metastasis was observed but a trend of low IKKα expression in non 
metastatic samples compared to metastatic ones was observed (Table 4.5). 
 
Table 4.5: Association of IKKα expression with clinicopathological features of 
breast cancer patients 
Clinicopathological 
Features 
Low Expression of 
IKKα 
 Total number (N) 
=74 
High Expression of 
IKKα  
 Total number (N) 
=74 P-value 
Age 
≤ 50 21 16 
0.044 >50 17 20 
Histological 
Grade 
II 
14 21 
0.814 III 4 5 
Lymph node 
status 
No metastasis 5 11 
0.270 Metastasis 10 10 
Progesterone 
Receptor 
Positive 14 12 
0.021 Negative 8 18 
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4.6.1 Association of IKKα Expression with Age 
IKKα is a crucial protein involved in the immune regulation and aging directly 
affects the immune status of an individual. Thus correlation of IKKα expression 
with age was analyzed in IDC tissue samples. Patients were categorized into two 
age groups, one of less or equal to 50 years (≤50) and the other of above 50 year 
(Table 4.5). IKKα expression was low in 21 samples of ≤50 years and 17 samples 
of >50 years of age while the expression of IKKα was high in 16 tissue samples of 
≤50 years and 20 samples of >50 years of age. Expression of IKKα was 
significantly low (p=0.044) in patients with age ≤50 years as compared to that of 
>50 years (Figure 4.19 and 4.20).  
4.6.2 Association of IKKα Expression with PR Status 
Aberrant activation of NF-κB provides mechanistic basis for breast cancers. 
(Ben-Neriah and Karin, 2011). Interaction between the hormonal receptors  and 
NF- B are already reported therefore, in order to analyze association of IKKα with 
hormonal receptors, IHC was brought about (Van Der Burg and Van Der Saag, 
1996). Here, IKKα expression was found to be low in 14 PR positive and 8 PR 
negative samples.  While the expression of IKKα was high in 12 PR positive tissue 
samples and 18 samples with PR negative status (Figure 4.21 and 4.22). Low 
expression of IKKα was significantly associated (p=0.021) with PR positivity. 
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                                     (a)                     (d)                                             
           
   (b)          (e) 
          
    (c)          (f) 
 
Figure 4.19: Immunohistochemical analysis of IKKα expression in invasive ductal 
carcinoma (IDC) patients of different age groups. Immunohistochemical staining 
with IKKα and histological comparison of IDC tissue samples was performed. 
Negative control (a,c), low expression of IKKα in patients of ≤50 years age (b,d) 
and high expression of IKKα in patients of >50 years of age (c,f) is shown. Images 
on left side (a, b, c) are captured at 40X magnification and on right side (d,e,f) are 
captured by 100X objective.  
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Figure 4.20: Histogram showing correlation of IKKα expression with age of IDC 
patients. Graph showing statistical comparison of IKKα expression in patients of 
≤50 years (Total number (N)=37) and >50 years (N=37).  
* Correlation is significant at the <0.05 level. 
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                                     (a)                     (d)                                          
           
   (b)          (e) 
          
    (c)          (f) 
Figure 4.21: Immunohistochemical analysis of IKKα expression in invasive ductal 
carcinoma (IDC) patients with Progesterone receptor (PR) positive and negative 
status. Immunohistochemical staining with IKKα and histological comparison of 
IDC tissue samples was performed. Negative control (a,c), low expression of IKKα 
in PR positive tissue samples (b,d) and high expression of IKKα in PR negative 
tissue samples (c,f) is shown. Images on left side (a, b, c) are captured at 40 X 
magnification and on right side (d,e,f) are captured by 100X objective.  
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Figure 4.22: Histogram showing correlation of IKKα expression with PR status of 
IDC patients. Graph showing statistical comparison of IKKα expression in IDC 
patients with PR negative (Total number (N =26) and PR positive (N=26) status.  
* Correlation is significant at the <0.02 level. 
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4.7 EVALUATION OF BREAST CANCER AWARENESS 
Pakistan has highest incidence and mortality rate of breast cancer among 
Asian countries (Bhurgri et al., 2000; Asif et al., 2014). One of the leading causes 
of BC related mortality is the late diagnosis in Pakistan. Lack of public awareness 
about preventable risk factors and early warning signs is main cause of late 
diagnosis. Increase in survival rate of patients can be achieved by a significant 
approach of persuading awareness in population, better screening and in time 
detection of breast cancer at an initial stage. The dissemination of basic knowledge 
about breast cancer risk factors and early signs in Pakistani students was found to 
be unsatisfactory (Noreen et al., 2015). The dissemination of basic knowledge 
about breast cancer risk factors and early signs in society can be carried out using a 
range of methods. One principally effective way is by educating young women 
while they are studying in educational institutes. No such study has ever been 
conducted in the Southern Punjab region of Pakistan. Therefore, as a side project 
this was intended to assess the awareness of the risk factors and early signs of 
breast cancer among the medical and non-medical students of university of 
southern Punjab, Pakistan (Noreen et al., 2015).  
4.7.1 Demographic characteristics  
The survey included 566 female university students of university from southern 
Punjab, Pakistan. 326 non-medical students were aged between 20-28 years while 
240 medical students ranged between 21-25 years. The mean age of non-the 
medical and medical participants was 23 years (SD 2.1) and 22 years (SD 1.3) 
respectively. Most of the students were Muslim. Majority of the non-medical; 199 
(61%) and medical students; 182 (76%) were residents of urban areas. 281 (86%) 
non-medical and 214 (89%) medical students belonged to Punjabi families. Among 
non-medical girls 309 (95%) were unmarried and 17 (5%) were married. The 
majority of medical participants; 238 (99%) were unmarried and only 2 (1%) were 
married (Table 4.6). 
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Table 4.6: Demographic characteristics of the participants 
 Non Medical Students 
N=326 
Medical Students 
N=240 
Characteristics n (%) n (%) 
 
Age 
Range (Years) 20-28 21-25 
Mean SD 23 2.1 22 1.3 
Religion Muslims 321 (99) 238 (99) 
Non Muslims 5 (1) 2 (1) 
Residency Urban 199 (61) 182 (76) 
Rural 127 (39) 58 (24) 
 
Ethnicity 
Punjabi 281 (86) 214 (89) 
Sindhi 13 (4) 7 (3) 
Pathan 4 (1) 0 (0) 
Baloch 21 (6) 9 (4) 
Other 7 (3) 10 (4) 
Marital Status Unmarried 309 (95) 238 (99) 
Married 17 (5) 2 (1) 
 
 
 
 
 
 
 
Chapter 4                                                                                                                     Results 
96 
 
4.7.2 Source of Information 
Most cited source of information by non medical students was television 
while medical students found their academic education to be the best source of 
information about breast cancer (Figure 4.23).  
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Figure 4.23: Histogram showing participant’s source of information about breast 
cancer 
4.7.3 Basic Knowledge about Breast Cancer  
The next portion of the questionnaire contained questions about basic 
knowledge about breast cancer. Most of the non-medical 239 (73%) and medical 
191 (80%) students knew that breast cancer is among the most prevalent cancers 
among women of Pakistan. But taken together across all the answers, knowledge 
of the students was not found to be satisfactory (less than 50% could give correct 
answer for most of the questions).  
Only 71 (22%) non-medical and 67 (28%) medical students had awereness 
that breast cancer can also affect men. The majority of non-medical 260 (80%) and 
medical students i.e 199 (83) had an information about breast cancer treatment. 
215 (90%) medical students had knowledge that breast cancer is not a contagious 
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disease. Their response was significantly better (p<0.05) than that of non-medical 
students as only 96 (29%) non-medical students had this information. 183 (56%) 
non-medical and 161 (67%) medical students were familiar with the possibility that 
a woman younger than 30 years can also develop breast cancer (Table 4.7). 
4.7.4 Awareness of Early Warning Signs 
The responses from medical students did not differ significantly (p > 0.05) 
from that of the non- medical ones about information regarding bloody discharge 
from nipple in a non-pregnant woman. Although the response of medical students 
to all other questions about noticeable indicators was significantly better (p < 0.05) 
than non-medical participants, but as a whole, the knowledge of both groups was 
inadequate. Most of the medical students (78%) knew that the pain in the breast 
does not always indicate the presence of breast carcinoma, but the presence of a 
lump in the breast can be a noticeable indicator (indicated by 90% medical 
students). Less than 35% students had knowledge about any potential indicative 
warning signs of breast cancer, for instance, change in the color or shape of nipple, 
change in skin color of the breast, bloody discharge from the nipple, the presence 
of a lump in the neck or armpit and asymmetry of the breasts (Table 4.8).  
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Table 4.7: Basic knowledge and perception about breast cancer 
 Non Medical Students  
N=326 
Medical Students 
N=240 
Questions Corr. 
Ans.  
n (%) 
Inco. 
Ans.  
n (%) 
D/K  
n (%) 
Corr. 
Ans.  
n (%) 
Inco. 
Ans.  
n (%) 
D/K  
n (%) 
Is breast cancer one 
among the most 
prevalent cancers in 
women of Pakistan? 
239 
(73) 
34 (10) 53 (16) 191 
(80) 
13 (5) 36 
(15) 
Can Breast cancer 
affect men? 
71 (22) 99 (30) 155 
(48) 
67 (28) 96 
(40) 
77 
(32) 
Can breast cancer be 
treated? 
260 
(80)  
19 (6)  47 (14) 199 
(83) 
22 (9) 19 (8) 
Is breast cancer a 
contagious disease? 
96 (29) 143 
(44) 
87 (27) 215 
(90) 
13 (5) 12 (5) 
Can a woman younger 
than 30 years get breast 
cancer? 
183 
(56) 
59 (18) 84 (26) 161 
(67) 
54 
(23) 
25 
(10) 
Note: Corr. Ans. = Correct Answer, Inco. Ans. = Incorrect Answer, D/K = Don’t 
Know, N = Total number of participants. n = Number of participants. 
 
 
 
 
 
Chapter 4                                                                                                                     Results 
99 
 
Table 4.8: Awareness about early warning signs 
 Non Medical 
Students  
N=326 
Medical Students 
N=240 
 
Questions Corr. 
Ans.  
n (%) 
Inco. 
Ans.  
n (%) 
Corr. 
Ans.  
n (%) 
Inco. 
Ans.  
n (%) 
p Value 
Pain in breast 149 (46) 177 (54) 187 (78) 53 (22) < 0.05 
Change in skin color of 
breast (redness) 
59(18) 267 (82) 73 (30) 167 (70) < 0.05 
Breast lump 137 (42) 189 (58) 216 (90) 24 (10) < 0.05 
Bloody discharge from 
nipple in a non-pregnant 
woman 
28 (9) 298 (91) 29 (12) 211 (88) > 0.05 
Change in the color or 
shape of a woman’s 
nipple 
31 (10) 295 (90) 65 (27) 175 (73) < 0.05 
Lump in neck or armpit 50 (15) 276 (85) 84 (35) 156 (65) < 0.05 
Asymmetry of the breasts  37 (11) 289 (89) 59 (25) 181 (75) < 0.05 
Note: Corr. Ans. = Correct Answer, Inco. Ans. = Incorrect Answer, D/K = Don’t 
Know, N = Total number of participants. n = Number of participants. 
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4.7.5 Awareness of Breast Cancer Risk Factors 
Our results showed that there is a widespread lack of awareness among 
female students about potential risk factors associated with the breast cancer. 
Knowledge of the medical students about risk factors such as family history of 
breast cancer (85% gave correct answer), combined hormone therapy after 
menopause (61% gave correct answer), and the use of oral contraceptive (68% 
gave correct answer) was significantly better (p < 0.05) than that of non-medical 
students of the university.  
98% of medical students knew that breastfeeding and giving birth to more 
than 5 children are not the risk factors for breast cancer. Interestingly, more non-
medical participants (64%) were aware of the misconception that the use of tight 
bra can cause breast cancer than the medical students (43%). Diabetes was known 
to be a risk factor for breast cancer by 37% non-medical and only 5% of the 
medical students may be due to a general concept that diabetes is a risk for a 
number of other diseases (Table 4.9). 
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Table 4.9: Awareness of breast cancer risk factors 
 Non Medical 
Students  
N=326 
Medical Students 
N=240 
 
Questions Corr. 
Ans.  
n (%) 
Inco. 
Ans.  
n (%) 
Corr. 
Ans.  
n (%) 
Inco. 
Ans.  
n (%) 
p 
Value 
Older age (>45 years) 44 (13) 282 (87) 110 (46) 130 (54) < 0.05 
Less Physical activity 62 (19) 264 (81) 19 (8) 221 (92)  < 0.05 
Use of tight bra for longer 
time  
208 (64) 118 (36) 104 (43) 136 (57)  < 0.05 
Being overweight / Obese   77 (24) 249 (76) 55 (23) 185 (77) < 0.05 
Consumption of fatty 
foods 
40 (12) 286 (88) 31 (13) 209 (87) > 0.05 
Combined hormone 
therapy after menopause 
53 (16) 273 (84) 146 (61) 94 (39) < 0.05 
Use of alcohol  68 (21) 258 (79) 73 (31) 167 (70)  < 0.05 
Diabetes  119 (37) 207 (63) 13 (5) 227 (95)  < 0.05 
Family history of breast 
cancer  
102 (31) 224 (69) 205 (85) 35 (15) < 0.05 
Dense breast tissue 25 (8) 301 (92) 43 (18) 197 (82) < 0.05 
Early menarche (<12 
years)  
22 (7) 304 (93) 20 (8) 220 (92) < 0.05 
Late menopause (>55 
years)  
19 (6) 307 (94) 31 (13) 209 (87)  < 0.05 
Oral contraceptive use  13 (4) 313 (96) 164 (68) 76 (32) < 0.05 
Past history of breast 
lumps  
73 (22) 253 (78) 122 (51) 118 (49) < 0.05 
Smoking 66 (20) 260 (80) 46 (19) 194 (81)  > 0.05 
Breast feeding  276 (85)  50 (15) 234 (98) 6 (2)  < 0.05 
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Chest radiation therapy 56 (17) 270 (83) 100 (46) 130 (54) < 0.05 
Having no children  19 (6) 307 (94) 23 (10) 217 (90) > 0.05 
Having more than 5 
children  
189 (58) 137 (42) 235 (98) 5 (2) < 0.05 
First childbirth after 30 
years  
22 (7) 304 (93) 17 (7) 223 (93)  > 0.05 
Note: Corr. Ans. = Correct Answer, Inco. Ans. = Incorrect Answer, D/K = Don’t 
Know, N = Total number of participants. n = Number of participants. 
 
4.7.6 Individual Score of Participants 
All the participants were categorized as poor, insufficient, satisfactory and 
good on basis of their score ranging from 1 to 32. Each successive category 
revealed difference of 25% increase in knowledge and awareness of breast cancer. 
Majority of non-medical students; 244 (75 %) and medical students; 131 (55 %) 
had insufficient knowledge (Table 4.10). 
 
Table 4.10: Categorical distribution of students on basis of breast cancer awareness 
Level of 
Knowledge 
Score Non-Medical Students  
N=326 
Medical Students 
N=240 
n (%) n (%) 
Poor ≤ 8 73 (22) 11 (5) 
Insufficient ≤ 16 244 (75) 131 (55) 
Satisfactory ≤ 24 9 (3) 95 (40) 
Good ≤ 32 0 (0) 3 (1) 
Note: Total number of participants. n = Number of participants. 
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Chapter 5 
DISCUSSION 
Cancer is the consequence of uncontrolled division of abnormal cells with 
the propensity to invade other parts of the body. Cancer is found to be the most 
frequent cause of death (accounting for 13 % of total deaths) worldwide. In last 
few decades tremendous research in the field of cancer biology has been carried 
out to understand the mechanism involved in the cancer progression but still there 
is much to be achieved (Hoesel and Schmid, 2013). Slew of still unanswered 
questions cued that cancer is actually a complex disease (Hayden and Ghosh, 
2012). Knowledge to date indicates that fortunately, one third of all cancers can be 
prevented and further one third can also be cured if diagnosed in time at an early 
stage (Parkin, 1994). 
Cancer initiation, sustenance and progression are strictly controlled by 
proper regulation of molecular activities as a signaling cascade. Physiological, 
physical, or/and oxidative stress of the tumor microenvironment deregulates these 
pathways, leading to uncontrolled cell division, escape from immune activation, 
smoldering inflammation and subsequent development of cancer (Ben-Neriah and 
Karin, 2011). Cancer pathogenesis involves regulation of well documented NF-κB 
signaling pathway (Hanahan and Weinberg, 2011). Aberrant activation of NF-κB 
in tumor microenvironment leads to excessive inflammation and cancer 
progression. By shaping various aspects of innate and adaptive immunity, NF-κB 
transcription factors are known to play an important role in chronic inflammation 
and tumorogenesis. 
Activity of NF-κB transcription factors is controlled by a group of non-
covalently associated inhibitory molecules called IκB. (Whiteside and Israel, 
1997). These inhibitors are phosphorylated and degraded by catalytic subunits of 
IKK complex; IKKα and IKKβ liberating NF-κB subunits to translocate to the 
nucleus where they bind to specific DNA targets as transcription factors to initiate 
transcription (Bonizzi and Karin, 2004; Hayden and Ghosh, 2012). NF-κB targets 
a number of genes involved in oncogenic cellular transformations (Figure 2.5). It 
fuels inflammation through production of COX-2 enzymes, inflammatory 
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cytokines such as TNFα, IL-1, IL-6 and IL-8, anti-apoptotic genes such as BCL-2, 
BCL-XL, CFLAR and cIAPs etc. (Basseres and Baldwin, 2006). IKKα and IKKβ 
have been reported to be involved in the endurance and development of cancers 
independent of NF-κB (Israel, 2010; Jiang et al., 2010). One of the ways can be 
through their direct interaction with proto-oncogene such as c-Myc. IKKs 
interaction with c-Myc has been reported but not much detail is known about their 
interaction; therefore the main focus of the current study was to gain better insight 
into the molecular details and effects of the association between IKKs and c-Myc.    
IKKα regulates transcription factors such as NF- B and E2F that are 
directly involved in the expressional regulation of a pleiotropic oncogenic Myc 
family of proteins (Wierstra and Alves, 2008; Levens, 2010). c-Myc belongs to 
the basic helix-loop-helix leucine zipper (bHLHLZ) containing family of 
transcription factors and is among the most well characterized and influential 
transcription factors as it is evidently involved in regulation of almost 15% of 
human genes (Xu et al., 2010). Extensive research during last three decades 
manifested the crucial role of c-Myc protein in cell growth (Henriksson and 
Luscher, 1996), proliferation (Lemaitre et al., 1996), apoptosis (Thompson, 1998), 
gene expression (Lee and Dang, 2006) and cancer metabolism (Miller et al., 
2012). Detailed structural analysis of IKKs and c-Myc are indicative of their 
interaction and effect of this co-operativity in oncogenic cellular transformation.  
IKKα is reported to constitutively shuttle between cytoplasmic and nuclear 
region of the cell (Hoesel and Schmid, 2013). c-Myc being a transcription factor 
resides mainly inside the nucleus. Live cell microscopy through FRET analysis 
was used to study the interaction between IKKs and cMyc. FRET analysis 
indicated that c-Myc directly interacts with IKKα inside the nucleus (Figure 4.1 
and 4.2). The association of IKKα with c-Myc was found to be more prominent as 
compared to IKKβ. In order to locate the interaction domain of IKKα with c-Myc, 
IKKα was truncated by cutting out HLH and LZ of IKKα. The lack of HLH and 
LZ domains resulted in disrupted interaction between IKKα and c-Myc (Figure 
4.3 and 4.4). This is the first evidence showing the indispensable role of HLH and 
LZ domains in IKKα in the association between IKKα and c-Myc. The disrupted 
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association between truncated IKKα and c-Myc could be either because the c-Myc 
interacting domain is located on HLH/LZ domains or the lack of these domains 
might have caused conformational changes in the IKKα protein which may inhibit 
the c-Myc to bind with IKKα. c-Myc is already reported to heterodimerize with 
other HLH/LZ domain containing proteins such as Max (Blackwood and 
Eisenman, 1991). Thus the disrupted interaction between c-Myc and HLH/LZ 
domains lacking IKKα (Figure 4.3 and 4.4) seem to indicate that HLH/LZ domain 
of IKKα protein can possibly be site of interaction with HLH/LZ domain of c-
Myc. 
Interaction of c-Myc with IKKβ was comparatively less evident than that 
of with IKKα. Probable reason could be the presence of IKKβ in cytosolic region 
while IKKα is reported to shuttle between nucleus and cytosol (Birbach et al., 
2002). Presence of IKKα and c-Myc in the nuclear region leads to their co-
localization in HEK 293 cells (Figure 4.3). However it was the first evidence of 
IKK interaction with c-Myc through FRET analysis in HEK 293 cells. The next 
question was to address the functional consequence of their interaction thus 
further study was conducted.  
Proteins often interact to either promote or inhibit each other’s function 
and activity. Therefore, the impact of interaction between IKKs and c-Myc was 
studied in cancer cell lines. Commonly, interacting proteins affect each other’s 
transcriptional regulation (Yeh et al., 2011) therefore it was intended to determine 
functional impact of IKKs and c-Myc interactions on each other at transcriptional 
and translational level. qPCR was carried out in order to find probable effect of 
this interaction on transcriptional level in HEK 293 cells. There was no significant 
effect of IKKs on transcription of c-Myc (Figure 4.5). These results are in line 
with a previous study carried out in breast cancer Michigan Cancer Foundation-7 
(MCF7) cell line (Yeh et al., 2011). Furthermore, over expression of c-Myc could 
also not result in any significant effect on transcription of IKKα (Figure 4.6) and 
IKKβ (Figure 4.7) in HEK 293 cells. 
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Results revealing no effect of c-Myc on the transcriptional expression of 
IKKα suggested that the interaction of both proteins could lead to some 
transcription-independent consequences in cancer cells. Therefore, in order to 
analyze the possible effect of c-Myc on protein expression and activity of IKKα, 
SDS-PAGE and western blot analysis was performed. Expression (Figure 4.8) and 
activity (Figure 4.9) of IKKα remained unaffected at translational level in 
response to the over expression of c-Myc in HEK 293 cells.  
As c-Myc is a transcription factor thus IKKs interaction could have some 
effect on its transcriptional activity. Luciferase assay was performed in order to 
analyze the possible effect of IKKs on transcriptional activity of c-Myc in 
LNCaps. Basal expression of c-Myc is lower in LNCaps as compared to HEK-293 
cells thus LNCaps were used to perform this experiment. Luciferase assay 
revealed notable decrease in the transcriptional activity of c-Myc in the presence 
of IKKα (Figure 4.10). This finding was further validated by using IKK inhibitors. 
For that cells were treated with inhibitor of IKK i.e. 10 μM Bay11-7082 for 12 
hours (Yeh et al., 2011). Increase in the transcriptional activity of c-Myc in 
presence of inhibitors confirmed the inhibitory effect of IKKα on transcriptional 
activity of c-Myc protein (Figure 4.11). Reduction in the transcriptional activity of 
c-Myc in the presence of IKKβ was also observed (Figure 4.12). Results were 
confirmed by treating cells with potent IKKβ inhibitor; 4 TPCA-1 for 12 hours. 
Increase in the transcriptional activity of c-Myc in the presence of inhibitor 
confirmed IKKβ to be responsible for indicated reduction (Figure 4.13).  
FRET analysis indicated that HLH/LZ domain of IKKα protein can 
possibly be site of interaction with HLH/LZ domain of c-Myc which is 
indispensable for its ability to recognize the promoters of target genes and turn on 
gene expression. Results of leuciferase assay indicate that IKKs probably down 
regulate the transcriptional activity of c-Myc by virtue of their ability to compete 
with the HLH/LZ domain of c-Myc for binding to other transcriptional regulators. 
Moreover, this study also indicated that IKKα and IKKβ tend to keep tumor cell 
environment less aggressive by decreasing transcriptional activity of an 
oncoprotein; c-Myc. 
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Further support in this regard is lent by IKKα expression in BC biopsies. 
High IKKα expression was observed to be more frequent in non metastatic 
samples as compared to metastatic ones. Although this was statistically non-
significant (P=0.270) but a trend was obvious and must be tested in large number 
of samples. IKKα, IKKβ and c-Myc are reported to be independently involved in 
the regulation of many genes related to cancer development. It seems as if c-Myc 
involved signaling pathway interacts with IKK involved signaling pathway to 
effect regulation of cancer cells. Further well defined studies are needed to 
characterize this interaction.  
In order to go into the structural detail of c-Myc interaction with IKKs it 
was intended to perform some in silico studies. So far no model of c-Myc is 
available. Detailed analysis of c-Myc sequence revealed that many SNPs are 
reported in this protein which are most frequent type of polymorphisms found in 
human genome (Noreen et al., 2012). Detailed information in this concern can be 
obtained using sequence and structure based tools of bioinformatics to select 
crucial and functional nsSNPs of c-Myc to get into deeply detailed research. In 
this study, some sequence and structural homology based algorithms were used to 
find those nsSNPs which can play a potential role in the structural and functional 
alteration of c-Myc proto-oncoprotein.  
In Burkitt lymphoma samples the c-Myc2 proto onco-gene contained a 
cluster of four significant SNPs in 2nd and 3rd exon (Rabbitts et al., 1983; Bhatia et 
al., 1993). VAR_063384 (Glu39Asp) involves substitution of Glutamate (E) to 
Aspartate (D) at position 39. Both amino acids are medium sized and acidic with 
similar physico-chemical properties. VAR_063385 (Pro57Ser) involves 
substitution of medium sized and hydrophobic Proline (P) to small sized and polar 
Serine (S) at position 57. VAR_063386 (Pro59Ala) involves substitution of 
medium sized and hydrophobic Proline (P) to small sized and hydrophobic 
Alanine (A) at 59th amino acid. VAR_063387 (Asn86Thr) involves substitution 
Asparagine (N) to Threonine (T) at position 86. Both amino acid residues are of 
medium size and polar with similar physico-chemical properties. VAR_063385 
(Pro57Ser) and VAR_063386 (Pro59Ala) at position 57 and 59 respectively are of 
more importance because these have an adjacent threonine residue at position 58. 
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Phosphorylation of serine at position 62 by extracellular signal regulated kinase 
(ERK) or CDK kinases increases Myc cellular stability. Then phosphorylation of 
threonine at position 58 is brought about by GSK3-β which triggers 
dephosphorylation of S62 by protein phosphatase 2A (PP2A) and subsequentely 
ubiquitin-mediated degradation is brought about through SCF-Fbwx7 (ubiquitin 
ligases) (Hann, 2006). Thus any variation in this domain can gain some biological 
importance affecting this series of phosphorylation, dephosphorylation and 
ubiquitinations. 
Total 27 nsSNPs were found in the coding region along with two frame 
shift mutations; rs35631115 and rs67856294, among total 165 SNPs related to 
longest isoform of c-Myc protein (Table 4.7). As the SNPs associated with disease 
risk are generally nsSNPs; involving substitution of amino acids. These SNPs are 
likely to bring structural and functional changes in the protein. Evaluation of the 
possible role of nsSNP in the coding region was main aim of this study. One SNP 
(dbSNPid: rs4645960) found at position 175 has Gly [G] amino acid in wild type 
protein, which can be substituted either by Cys [C] or by Arg [R]. Both variants 
were considered separately to find if they have different effects. In order to find 
tolerant or deleterious effect of amino acid exchange on protein function, the SIFT 
algorithm (Ng and Henikoff, 2001) was used which is specialized in aligning 
homologous sequences, considers physical properties of amino acids and possible 
effects of naturally occurring nsSNPs on protein. Total 8 nsSNPs were found to be 
deleterious, out of which 2 had low confidence due to scarcity of available 
sequences for alignment (Table 4.2).  
PolyPhen-2 server (Adzhubei et al., 2010) was used to forecast structural 
and functional effects of the SNPs of interest. PolyPhen searched for homologous 
protein sequences and 3D protein structures to predict the possible potential 
influence of variants on protein. Among total 27 variations, 7 were predicted to be 
probably damaging, one variant as possibly damaging while all others were 
considered to be benign (Table 4.3). Effect of four nsSNPs lying in coding region 
of c-Myc; rs114570780 (Tyr47His), rs150308400 (Cys148Tyr), rs137906262 
(Leu159Ile) and rs200431478 (Ser362Phe) were predicted by SIFT algorithm to 
be intolerant and by PolyPhen-2 server to be probably damaging (Figure 4.17).  
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Four nsSNPs; rs4645959 (Asn26Ser), rs114570780 (Tyr47His), 
rs150308400 (Cys148Tyr) and rs137906262 (Leu159Ile) were located within N-
terminal trans-activation domain of c-Myc1 containing 2 highly conserved 
domains called MBI and MBII. In c-Myc1 the MBI will range approximately 61-
78 amino acids and MBII will span region of 144-158 amino acids (Figure 4.15). 
This region harboring MBI and MBII is essential for transactivation of target 
genes involved in process of apoptosis, cell proliferation and transformation 
(Wirtenberger et al., 2005). In MBI domain a series of potential phosphorylations 
by MAPK, CDKs or GSK3β take place in cell cycle dependent manner.  
These phosphorylation events regulate transcription and transformation. 
MBII encodes the hydrophobic part of the c-Myc protein. One Transcription 
activation domains (TAD) is located upstream of MBI and the other is upstream 
and overlapping region of MBII. A repression element is identified between the 
MBI and MBII domains while other overlaps MBII itself (Sakamuro and 
Prendergast, 1999). N-terminal trans-activation domain is also reported to interact 
with TBP, α-Tubulin, p107 as well as adaptor proteins; TRRAP, AMY-1, Bin1, 
Pam, and MM-1 (Beijersbergen et al., 1994). Thus, interaction of these proteins 
and presence of sequences related to activation or repression activity in N-
terminal trans-activation domain suggests its key role in apoptosis, chromatin 
modeling, cell cycle and transcriptional regulation (Sakamuro and Prendergast, 
1999). Presence of genetic variants in this region can effect this regulation 
significantly.  
The rs4645959 involves substitution of medium sized Asparagine (N) to 
small sized Serine (S) residue. According to SIFT Prediction this variant is 
intolerant (Tolerance index = 0.01). This nsSNP was reported to be putatively 
functional being capable of altering the secondary structure of protein. 
Heterozygous carriers of this variant among Polish and German individuals were 
observed to have an increased risk of familial breast cancer (Wirtenberger et al., 
2005). Two nsSNPs; rs141095253 (Pro397Leu) and rs145561065 (Leu434Phe) 
are found within while rs200431478 (Ser362Phe) is located near the C-terminal 
domain which spans 375-452 amino acid region of c-Myc1 (Figure 4.15). This C-
terminal DNA binding segment contains BR-HLH-LZ domain. Another BR-HLH-
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LZ domain containing protein; Max is identified as a closely related, obligate and 
physiological heterodimerization partener of c-Myc (Blackwood and Eisenman, 
1991).  
The HLH-LZ domains of both proteins form strong heterodimers and 
recognize the E-Box containing promoters to regulate transcriptional activation, 
cellular transformation, cell cycle progression and apoptosis (Amati et al., 1993). 
Other than Max some proteins like Nmi, TFII-I, YY-1, AP-2, BRCA1 and  Miz-1  
are also reported to interact with C-terminal region of c-Myc. Based on these 
interactions, C-terminal region is supposed to control the access of  the N-terminal 
trans-activation domain to specific genetic loci (Sakamuro and Prendergast, 
1999). Presence of nsSNPs in C-terminal region can alter these interactions and 
consequently can lead to an impaired functioning of c-Myc protein in cell. 
However, when these SNPs were subjected to SNPeffect server to weigh up their 
possible effect on molecular phenotype of protein, most of the variations were 
neither predicted to affect aggregation tendency and amyloid propensity nor the 
chaperone binding tendency of c-Myc protein (Table 4.4).  
It seems as, if these variations are really capable of bringing some 
damaging alterations to c-Myc, then these are certainly other than the aggregation 
tendency, amyloid propensity and the chaperone binding tendency of the protein 
as per prediction of SNPeffect. Chaperone binding tendency and protein stability 
of c-Myc was shown to be decreased by only Pro/Leu variation at position 397 
(rs141095253). Further analysis can be performed using some other computational 
tools and availability of PDB structure can help in making more precise and 
reliable evaluations. Results of this study can be helpful and interesting especially 
to those epidemiologists who are interested in large-scale population based 
studies. Moreover, on basis of our predictions, the real effect of nsSNPs 
particularly rs114570780 (Tyr47His), rs150308400 (Cys148Tyr), rs137906262 
(Leu159Ile) and rs200431478 (Ser362Phe) on c-Myc can be assured by 
conducting well defined in vitro and in vivo experimental studies. 
The capability of IKKα to shuttle in and out of the cellular nuclei and 
cytoplasm and to interact with cMyc indicates an important role of IKKα in 
oncogenesis. Unfortunately, the data in this regard is somehow controversial yet 
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crucial for its potential therapeutic exploitation. IKKα has been reported to play 
pro-tumorogenic as well as anti-tumorogenic role. To explore the molecular 
details and ultimate role of IKKα one of the objectives included the expressional 
analysis of IKKα in breast cancer tissue samples and its correlation to 
clinicopathological features of Pakistani BC patients. In this study, 
Immunohistochemistry was carried out for in vivo expressional analysis of IKKα 
in 83 IDC tissue samples and its correlation to clinicopathological features of 
Pakistani BC patients was determined. Results of 9 samples were not predictable 
probably due to improper formalin fixation thus were excluded from the study. 74 
remaining samples included 37 patients aged ≤50 years while 37 were of >50 
years. 26 samples with PR positive status and 26 with PR negative status were 
stained and analyzed (Table 4.5). IKKα expression was categorized as low or high 
depending on percentage of IKKα positive cells in IDC tissue samples. The 
immune system is specialized to detect and correct the cell defects. Aging directly 
affects the immune status of an individual and damages immune competency. 
Undesirable changes in the immune system are evidently associated with aging. 
This down regulation of immune system increases the rate of cancer related 
morbidity and mortality in the elderly age (Wu and Meydani, 2014).  
IKKα is a crucial protein involved in the immune regulation. In this study 
IKKα expression was found to be low in 21 samples taken from patients of ≤50 
years and 17 samples of >50 years of age while the expression of IKKα was high 
in 16 tissue samples of ≤50 years and 20 samples of >50 years of age. Expression 
of IKKα was significantly low (p=0.044) in patients with age ≤50 years as 
compared to that of >50 years (Figure 4.19 and 4.20). Results indicate the 
association of aging with elevated expression of IKKα in patients of >50 years of 
age which may be indicative of poor prognosis.  
Histological grade directly affects the propensity to invasion and 
metastasis of breast cancer. Low grade tumors morphologically resemble normal 
cells and are well differentiated while high grade tumors are highly 
undifferentiated. Highly undifferentiated cells are more likely to invade 
surrounding organs of the body causing metastasis and poor prognosis 
(cancer.gov, 2014). Metastasis is the hall mark of breast cancer. A cancer escapes 
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the immune surveillance by invading the lymph and blood vessels gaining ability 
to metastasize to distant organs of the body. However, IKKα expression was not 
found to be significantly associated with the histological tumor grade and lymph 
node metastasis. Possible reason for this finding can be less number of available 
samples. Further studies involving more number of samples can help to elucidate 
probable association of IKKα with histological tumor grade and lymph node 
metastasis in IDC.  
PR and NF- B are already reported to suppress each other’s activity (Van 
Der Burg and Van Der Saag, 1996) and the regulation of NF- B is brought about 
through IKKα, thus expressional analysis of IKKα in PR positive and negative 
samples was brought about in IDC samples. IKKα expression was found to be low 
in 14 PR positive and 8 PR negative samples.  While the expression of IKKα was 
high in 12 PR positive tissue samples and 18 samples with PR negative status 
(Figure 4.21 and 4.22). Low expression of IKKα was significantly associated 
(p=0.021) with PR positivity. As PR and NF- B are reported to suppress each 
other’s activity (Van Der Burg and Van Der Saag, 1996)  thus suppression of NF-
 B in tumor microenvironment can be result of low expression of IKKα. May be 
decrease in level of IKKα helps to make cancer cell microenvironment less 
aggressive in PR positive BC patients as compared to PR negative. Thus, it seems 
to play a crucial role in proper regulation of NF- B pathway and its association 
with PR status in BC patients.   
While collecting BC biopsy samples, it was observed that a significant 
number of BC patients had a low literacy rate. Therefore, we hypothesized that 
one of the factors for increase in the incidence and mortality rate of breast cancer 
in Pakistan could be lack of awareness about BC and its late diagnosis (Bhurgri et 
al., 2000; Asif et al., 2014). BC is a health risk for women of all ethnic and social 
groups. Commonly Pakistani women are struck by it at a younger age and 
diagnosed at an advanced stage as compared to women of the western world 
(Rasheed, 2013). Late stage diagnosis usually involves metastasis and is hard to 
treat thus, reduces the survival rate. Likelihood of up to 5 years survival is about 
85% among the cases diagnosed at an early stage while it reduces to just 10% 
among cases diagnosed at stage IV (Gilani et al., 2003). Increase in survival rate 
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of patients can be achieved by a significant approach of persuading awareness in 
population, better screening and in time detection of breast cancer at an initial 
stage. The dissemination of basic knowledge about breast cancer risk factors and 
early signs in society can be carried out using a range of methods. One principally 
effective way is by educating young women while they are studying in 
educational institutes. Therefore, as a side project, this study aimed to assess the 
awareness of the risk factors and early signs of breast cancer among the medical 
and non-medical students of university of southern Punjab, Pakistan (Noreen et 
al., 2015). Results show a widespread lack of knowledge regarding BC among 
non-medical and medical university students (Table 4.10). These results are in line 
with numerous studies conducted in other countries (Ahmed, 2010; Sait et al., 
2010; Yadav and Jaroli, 2010; Al-Naggar et al., 2011; Sambanje and Mafuvadze, 
2012; Kurtuncu et al., 2014). Although, the perception of medical students was 
comparatively better as compared to that of non-medical ones, but their overall 
knowledge was still generally insufficient. Level of knowledge regarding breast 
cancer did not differ among the respondents of different age, residency, religion, 
ethnicity or marital status.  
This study highlighted the inadequate awareness about the potential risk 
factors among young women in Southern Punjab, Pakistan. Some BC risk factors 
are inevitable such as family history, diabetes, nature of the breast tissue, early 
menarche and late menopause etc., but some other factors such as diet, alcohol 
consumption, smoking, physical activity, hormone therapy and use of oral 
contraceptives can be controlled. The awareness regarding the healthy lifestyle 
adjustments can help to reduce the disease burden of society. Awareness of both 
the groups was poor concerning potential risk factors such as age, being obese, 
being physically inactive, intake of fatty food, diabetes, dense breast tissue, 
smoking, early menarche, late menopause, having no children and first childbirth 
after the age of 30 years. Crucial reproductive decisions are generally made at an 
age to which mostly university students belong, for example, time of first child’s 
birth, use of oral contraceptives and period of breastfeeding etc. Only proper 
awareness can lead them to better decisions making and modification of lifestyle 
to decrease the risk of breast cancer.  
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This study shows a general lack of understanding among both groups of 
university students. These findings further highlight the need of immediate 
measures to increase awareness and thereby reduce the high morbidity and 
increasing mortality of women due to breast cancer. A proper platform should be 
established for health care providers and educationists. In this way they can 
educate women to be safe from preventable risk factors, and the early warning 
signs of disease. Internet social media, mass media, and non-government 
organizations (NGO) should step forward to foster the transfer of life-saving 
knowledge to as many people as possible. Special awareness programs, lectures, 
seminars, training courses and workshops should be conducted at educational 
institutes regularly. This will lead to in time diagnosis, cost effective treatment 
and a reduction of the burden that this killer disease places on society.  
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Conclusion 
Cancer is a group of diseases involving abnormal cell growth with the 
propensity to invade or spread to other parts of the body. Cancer progression is 
principally regulated by NF- B which is controlled by IKKs. IKKα, IKKβ and c-
Myc are reported to be independently involved in the regulation of many genes 
related to cancer development. Physical interaction of IKKα with c-Myc and 
reduction of transcriptional activity of c-Myc by IKKs indicates interaction of c-
Myc involving signaling pathways with IKK involving signaling pathways to 
effect regulation of cancer cells. Further well defined studies are needed to 
characterize this interaction. Results of In Silico study can be helpful and 
interesting especially to those epidemiologists who are interested in large-scale 
population based studies. Moreover, on basis of our predictions, the real effect of 
nsSNPs particularly rs114570780 (Tyr47His), rs150308400 (Cys148Tyr), 
rs137906262 (Leu159Ile) and rs200431478 (Ser362Phe) on c-Myc can be assured 
by conducting well defined in vitro and in vivo studies. Pakistan has highest 
incidence and mortality rate of breast cancer among Asian countries. Low 
expression of IKKα in PR positive tissue samples of IDC patients was observed.   
This study shows a general lack of understanding about potential risk factors and 
early warning signs of breast cancer in general population. This awareness is 
necessary to decrease morbidity and mortality of breast cancer. These findings 
further highlight the need of immediate measures to increase awareness among 
people by establishing a proper platform for health care providers and 
educationists which can lead to the in time diagnosis, cost effective treatment and 
a reduction of the disease burden. 
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Detail of Tissue Samples of invasive ductal  
carcinoma (IDC) patients 
S. No. Age PR 
Status  
Histological 
Grade 
Lymph 
Node 
Invasion 
IKKα 
Staining  
s1 50 Negative II Metastasis  Low 
2 65 Negative     Unpredictable 
3 60 Positive   Low 
4 62 Negative   High 
5 72 Positive   Low 
6 47 Positive   High 
7 59 Positive   Low 
8 60 Negative II Metastasis  High 
9 61 Positive II Metastasis  Low 
10 58 Negative III Metastasis  High 
11 61 Positive III Metastasis  High 
12 50 Negative III Metastasis  Low 
13        Unpredictable 
14 40 Negative II Metastasis  High 
15 35 Negative II Metastasis  Low 
16 45 Negative   Low 
17 32 Negative II  High 
18 58 Negative     Unpredictable 
19 60 Negative II Metastasis  High 
20 51 Negative II  High 
21 64 Positive   High 
22 37 Positive II  Low 
23 50 Negative II Metastasis  Low 
24 42 Positive II No 
Metastasis  
Low 
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25 45 Negative   Unpredictable 
26 60 Positive II No 
Metastasis  
Low 
27 50 Negative II Metastasis  Low 
28  71      Low 
29 50 Negative II No 
Metastasis  
High 
30        Unpredictable 
31 67 Negative     Unpredictable 
32 71 Positive   High 
33 40 Negative III  Low 
34  66      Unpredictable 
35 65 Positive  Metastasis  Low 
36 42 Negative II  Low 
37 55 Negative   High 
38 50 Negative II No 
Metastasis  
High 
39 35 Positive II  Low 
40 53 Positive II  High 
41 70 Negative   High 
42 48 Negative II Metastasis  High 
43 33 Negative   High 
44 53 Negative II No 
Metastasis  
High 
45 42 Negative     High 
46 50    Low 
47 48 Positive  No 
Metastasis  
High 
48 50 Positive II  High 
49 55 Negative II  High 
50 64 Positive   Low 
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51 30 Positive   Low 
52 46    Low 
53 48 Positive II  Low 
54 80    Low 
55 32 Positive   Low 
56 58 Positive   Low 
57 61      Unpredictable 
58 51 Positive II Metastasis  High 
59 45  Positive II No 
Metastasis  
High 
60 50    Unpredictable 
61 44 Positive   High 
62 68   Metastasis  Low 
63 57    Low 
64 62    Low 
65 71 Positive II  High 
66 53    Low 
67 36    Low 
68 51      Low 
69 43  Negative III Metastasis  High 
70 57 Negative III No 
Metastasis  
High 
71 55 Positive III No 
Metastasis  
High 
72 40  II No 
Metastasis  
Low 
73 36  II No 
Metastasis  
Low 
74 60  II No 
Metastasis  
High 
75 45  II Metastasis  High 
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76 59  III Metastasis  Low 
77 34  II No 
Metastasis  
High 
78 70  III Metastasis  Low 
79 25  II No 
Metastasis  
High 
80 34    Low 
81 73   II Metastasis  High 
82 52  II No 
Metastasis  
High 
83 35  II No 
Metastasis  
Low 
 
 
 
